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AMP-activated protein kinase, AMPK, is a conserved serine/threonine kinase 
with a critical function in the regulation of metabolic pathways in eukaryotic cells.  
Recently, AMPK has been shown to play an additional role as a regulator of 
inflammatory activity in leukocytes.  Treatment of macrophages with chemical AMPK 
activators, or forced expression of a constitutively active form of AMPK, results in 
polarization to an antiinflammatory phenotype.  Additionally, we reported previously that 
stimulation of macrophages with antiinflammatory cytokines such as IL-10, IL-4 and 
TGF-β results in rapid activation of AMPK, suggesting that AMPK contributes to the 
suppressive function of these cytokines.  In the current study we investigated the role of 
AMPK in the regulation of macrophage antiatherogenic functions and demonstrated a 
new mechanism for AMPK’s role in mediating IL-10-induced gene expression and 
antiinflammatory effects.  The expression of dominant negative (DN-) AMPKα1 in 
macrophages resulted in a spontaneous obese phenotype in mice associated with fatty 
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liver and heart enlargement.  The expression of constitutively active (CA-) AMPKα1 in 
macrophages resulted in decreased IL-6 production but increased expression of ABCA1 
and ApoE.  Compared to wild-type macrophages, AMPKα1-deficient macrophages failed 
to express atheroprotective genes including ApoE, LXRα, and ABCA1 in response to IL-
10.  Mechanistic studies revealed that IL-10-stimulated wild-type macrophages displayed 
rapid activation of PI3K and its downstream target Akt, an effect that was not seen in 
macrophages generated from AMPKα1-deficient mice.  Treatment with the PI3K 
inhibitor LY294002 blocked IL-10’s ability to induce Akt activation but not AMPK 
activation, suggesting that IL-10-mediated activation of AMPK is independent of PI3K.   
CA-AMPKα1 macrophages displayed elevated PI3K and CREB activation in response to 
IL-10 compared to the empty vector transfected macrophages.  IL-10 stimulation resulted 
in increased mTORC1 activity, an Akt downstream target, an effect that was reduced in 
AMPKα1-deficient mice.  IL-10 induced phosphorylation of both Tyr705 and Ser727 
residues of STAT3 in an AMPKα1-dependent manner, and these phosphorylation events 
were blocked by inhibition of CaMKKβ, an upstream activator of AMPK, and by the 
mTORC1 inhibitor rapamycin, respectively.  The impaired STAT3 phosphorylation in 
response to IL-10 observed in AMPKα1-deficient macrophages was accompanied by 
reduced SOCS3 expression and an inadequacy of IL-10 to suppress LPS-induced 
proinflammatory cytokine production.  Overall, our data demonstrate that AMPKα1 is 
required for IL-10 activation of the PI3K/Akt/mTORC1 and STAT3/SOCS3 
antiinflammatory pathways regulating macrophage polarization, a mechanism with 
broad-reaching applicability in immune homeostasis and in inflammation-associated 
diseases such as atherosclerosis, autoimmune diseases, and obesity.
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Macrophages are important players of the innate immune system.   They display 
profound phenotypic and functional heterogeneity due to their ability to adapt to the 
tissue microenvironment (1).   A variety of mediators in the microenvironment including 
type 1 cytokines such as IFNγ and IL-12 (2, 3), or type 2 cytokines such as IL-4, IL-10 
and TGFβ (4-7) are able to promote macrophage development and activation toward pro- 
or anti- inflammatory functional patterns.  The changes of the cytokine profile in the 
microenvironment induce macrophage subsequently shift their functional phenotypes, 
and display highly balanced patterns of inflammatory features (7, 8).  The AMP-activated 
protein kinase (AMPK) has been well established as a regulator of energy homeostasis in 
eukaryotic cells and recent research suggests an important role of AMPK as a counter-
regulator in many inflammatory processes (9-13).  Our previous studies have shown that 
AMPK responds to either pro- or anti- inflammatory stimuli and plays a key regulatory 
role in macrophage and dendritic cell (DC) inflammatory functions (14, 15).  Changes of 
macrophage inflammatory functions contribute greatly to the progression or regression of 
atherosclerosis (16, 17).  Many AMPK-regulated metabolic and inflammatory signaling 
pathways are reported to be protective in atherosclerosis (18, 19).  However, the role of 




MACROPHAGE FUNCTIONAL PLASTICITY 
Macrophage development and heterogeneity  
The mononuclear phagocyte system comprises monocytes, macrophages, and 
their lineage-committed precursors (20).  The monocyte precursors are generated from 
hematopoietic stem cells in the bone marrow, and then monocytes exit the bone marrow, 
circulate in the blood, and can enter tissues under inflammatory conditions.  They give 
rise to subsets of macrophages and inflammatory DCs (21).  Macrophages are phagocytic 
leukocytes that are present in all tissues of the body.  According to the specific tissues 
that macrophages reside in, they are given unique names such as microglia (central 
nervous system, CNS), osteoclasts (bone), alveolar macrophages (lung), Langerhans cells 
(skin), Kupffer cells (liver), etc. (22).   
Macrophages display extremely plastic characteristics to reversibly adapt to the 
changes in the microenvironment and subsequently modulate both innate and adaptive 
immune responses (1, 7, 8).   Depending on what agents they encounter in the blood, 
circulating macrophage precursors enter different tissues where they are influenced by 
the tissue-specific microenvironment, resulting in alterations of their maturation and 
development of tissue specific function pattern.  A large spectrum of microenvironment 
factors has been shown to induce macrophage activation and acquisition of functional 
phenotypes.  These factors include bacterial moieties, antibody immune complexes, 
cytokines, chemokines, fatty acids, and stress hormones (7, 22, 23).  Stimulation by one 
factor alone, or in combination, results in macrophage performance of a wide range of 
activities, many are opposite to one another (7).  The variety of macrophage activities 





Figure 1. Macrophages perform functional heterogeneity in microenvironment.  
Macrophages express a variety of functions in response to different changes in their 
microenvironment.  Macrophages can exhibit both proinflammatory and 
antiinflammatory activities such as secretion of proinflammatory cytokines, chemokine, 














acute or chronic inflammation, antigen presentation, wound healing, cytotoxicity, etc. 
(Fig. 1).  
 
Macrophage activation and polarization  
Macrophage activation was originally categorized in two distinct states of 
polarization: the classically activated macrophage phenotype and the alternatively 
activated macrophage phenotype.  Before the publication in 1992 of Stein et al., 
demonstrating a newly discovered effect that IL-4 stimulation enhanced mannose 
receptor expression in macrophages (4), research was focused on macrophage activation 
by Th1 cytokine IFNγ and TNFα to enhance macrophage cytotoxicity (24).  This 
discovery, along with subsequent studies, established that IL-4 stimulation is able to up-
regulate a distinct set of genes in macrophages.  These IL-4 activated macrophages were 
then defined as “alternatively activated” macrophages, in contrast to the previously 
described IFNγ/TNFα activated macrophages, referred to as “classically activated” 
macrophages (25).  Based on the cytokines that are associated with these macrophage 
phenotypes, the nomenclature of M1/M2 was designated to the classically or alternatively 
activated macrophages, respectively, mirroring the T helper type 1 (Th1)/T helper type 2 
(Th2) paradigm.  The classically activated macrophages (M1) are usually modeled by in 
vitro stimulation with IFNγ/or LPS stimulation, and are associated with increased 
microbicidal activity, antigen-presenting functions, and tissue destructive functions.  
They express elevated genes that are associated with increased proinflammatory features 
such as MHC class II molecules, nitric oxide synthase 2 (NOS2), IL-12, TNFα, IL-6, etc.  




with IL-4 or IL-13, and are associated with the antiinflammatory functions linked to 
wound healing, fibrosis, tissue repair, allergy, parasite infection, and tumor progression.  
Elevated antiinflammatory gene expression was observed in M2 including IL-10, TGFβ, 
arginase 1 (Arg 1), and mannose receptor 1 (MR), etc. (26, 27).    
Although the M1/M2 classification persists, a growing body of research suggests 
much more complex macrophage activation/polarization paradigms.  For example, a shift 
of inflammatory M1 phenotype to antiinflammatory M2 phenotype of macrophages was 
observed in many disease courses such as sepsis, cancer, obesity, and bacteria infection 
(26).  Combination of different stimuli, such as immune complexes + LPS/IL-1, IL-10 + 
LPS, IL-10 + IL-4 and IL-13, induced macrophage expression of subset of genes that are 
shared by both M1 and M2 phenotype (28).  Vastly different gene expression was found 
in macrophages isolated from different mouse strains, and in macrophages stimulated 
with LPS for short (0-6h) versus long (12-24h) time span (29), suggesting that the 
functional changes expressed by macrophages in response to stimuli is a response process 
rather than static.  This is also evidenced by the report that the production of IL-12 and 
TNFα induced by LPS stimulation is significantly repressed by adding IL-4 
simultaneously into the macrophage culture, whereas pre-treatment with IL-4 for > 20 h 
prior to LPS stimulation led to an opposite effect of enhanced IL-12 and TNFα 
production (30).   
 
Macrophage functional plasticity and regulation 
Studies in our lab have demonstrated that macrophages express remarkable 




This enormous variety of functional patterns expressed by macrophages is highly 
dependent on the microenvironment.  In this context, different organs and tissues are 
viewed as distinct microenvironments.  For example, the burden of endotoxin and 
particulate material from the portal circulation in liver provides a highly proinflammatory 
microenvironment, which is significantly different than the antiinflammatory 
microenvironment presented by immune privileged sites such as the eye and the brain.  
These distinct microenvironments provide unique subsets of stimuli that favor 
macrophage expression of organ specific functions (1).  This perspective is supported by 
our observation of macrophage phenotypic shifts with changes in the microenvironment 
(7).  By adding a variety of stimuli including IFNγ, IL-4, IL-10, IL-12, and FcR ligand 
for different durations pre- or post- LPS stimulation, macrophages express different 
cytokine expression patterns that cannot be classified entirely as M1 or M2.  These 
functional patterns of macrophages could be switched by alterations in the 
microenvironment by adding different combination of the stimulating reagents.  And 
these phenotypic changes could be reverted back to the original, untreated state by 
removing the reagent treatment from the culture for 1-2 days.  These data clearly 
demonstrated a remarkable ability of macrophages to reversibly adapt to the 
microenvironment (7), and raised the question of the macrophage heterogeneity over the 
whole body is a result of differentiation of distinct subsets or a result of differential 
regulation by the microenvironment.   
With the goal of identifying the mechanisms that manage macrophage functional 
plasticity, we found a master regulator of macrophage functions, AMP-activated protein 




quickly deactivated AMPK while stimulation with the antiinflammatory stimuli such as 
IL-10, TGFβ, and IL-4 increased AMPK activation.  Activation of AMPK leads to 
inhibition of LPS-induced proinflammatory signaling pathways and cytokine production.  
Elevated AMPK activity promoted production of antiinflammatory cytokine production 
in macrophages, polarizing macrophages towards an antiinflammatory direction (14).  
This study has continued our keen interest in seeking the role of AMPK in regulating 
macrophage inflammatory plasticity in homestasis and in disease. 
 
AMPK 
AMPK is a heterotrimeric protein kinase complex.  Its orthologous are expressed 
with highly conserved features in almost all eukaryotes, mammals, fungi, and even in 
plants (31).  This indicates that its ancestral form emerged at least a billion years ago.  
The discovery of AMPK goes back to 1970s, when microsomal 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMG-CoA reductase) (32) and acetyl-CoA 
carboxylase (ACC) (33) were found to be regulated by an upstream regulatory kinase by 
phosphorylation/ inactivation respectively, both of which were stimulated by AMP.  Later 
in 1987, Carling et al., provided evidence to show that both HMG-CoA reductase and 
ACC were regulated by the same protein kinase, namely AMP-activated protein kinase 
(AMPK) (34), and this name became official (35, 36).   The structural analysis of 
mammalian AMPK was achieved based on the successful purification and sequencing of 
this protein kinase in 1994 (37, 38).  Since the identification of AMPK, a burst of 
research emerged in the past decades exploring its regulation and function.  Based on its 




(39), resulting in shutting off ATP-consuming biosynthetic pathways while turning on 
ATP-generating catabolic pathways (31, 40, 41), most of the research has focused on the 
role of AMPK as an energy gauge to regulate metabolic biological processes in the body.  
Interestingly, recent studies also suggest an important role of AMPK in regulating 
inflammatory responses and diseases including atherosclerosis, obesity, cancer, etc. (10, 
11).   
 
AMPK structure and expression 
The AMPK heterotrimeric complex contains a catalytic subunit (α) and two 
regulatory subunits (β and γ).  Each subunit has different isoforms in mammalian cells 
encoded by distinct genes that are distributed across five chromosomes.  The 
corresponding genes that are related to the subunit isoforms (α1, α2, β1, β2, γ1, γ2, γ3) 
are named PRKA following by the subunit identifier (PRKAA1, PRKAA2, PRKAB1, 
PRKAB2, PRKAG1, PRKAG2, PRKAG3) (42).   
These subunits are differentially expressed in different tissues.  The AMPKα1 
isoform is evenly distributed across liver, kidney, lung, heart, red vastus, and brain, with 
higher levels in adipose tissue and lower levels in white vastus, spleen, and pancreas.  
The AMPKα2 isoform shows highest expression levels in the red vastus, followed by 
white vastus then heart kidney and liver, with very low levels seen in the lung, brain, and 
adipose tissue and negligible amounts in the pancreas and spleen (42).  We reported in 
2008 that the AMPKα1 isoform is highly expressed in both human and murine 
macrophages with no detectable AMPKα2 isoform expression (14).  The AMPKβ1 




profile in skeletal muscle and heart to a lesser extent.  The AMPKγ1 subunit is 
ubiquitously expressed.  The AMPKγ2 isoform is also widely expressed but highest in 
the heart, followed by brain, placenta, and skeletal muscle.  The AMPKγ3 isoform shows 
the most restricted expression, as it is confined to skeletal muscle (42). 
The mammalian AMPKαβγ heterotrimer exists in solution as a single monomer.  
Structural analysis revealed the α subunit contains an NH2-terminal kinase catalytic 
domain, an auto-inhibitory sequence, and a β subunit-binding domain.  The β subunit 
mainly serves as a subunit-binding platform that contains both α and γ subunits-binding 
domains.  The γ subunit contains four adenine-nucleotide binding sites (CBS domains).  
Other than one out the four motifs (CBS2) that doesn’t bind to nucleotide, two of them 
(CBS1 and CBS3) allow allosteric AMP binding and ready ATP exchange and one 
(CBS4) allows only nonexchangeable AMP binding with approximately 30-fold stronger 
binding affinity (41-43).  Recent studies revealed that binding of AMP to CBS1 mediates 
allosteric activation of AMPK, whereas binding of AMP or ADP to CBS3 is correlated 
with ADP protective effect against dephosphorylation (43-45).  
 
AMPK activation and regulation 
It is well established that binding of AMP or closely related AMP analogues to the 
AMPKγ subunit induces allosteric activation of AMPK by up to ~5 fold (10, 45).  In 
addition to its allosteric activation effect, binding of AMP was also proposed to promote 
the phosphorylation of the AMPKα1 Thr172 residue (46), although the underlying 
mechanism was unclear until a recent report in 2011 by Xiao et al., suggesting individual 




provided evidence that a tighter association of AMP to the CBS1 binding site is 
responsible for AMPK allosteric activation, while AMP or ADP binding to the relatively 
loose binding site CBS3 induces a conformational change of AMPK that promotes 
phosphorylation on AMPKα1 Thr172 residue and protects against dephosphorylation.   
Compared to allosteric activation, AMPK activation by upstream kinase 
phosphorylation at the Thr172 residue within the activation loop segment of α1 subunit 
catalytic domain reaches a much higher degree of more than 1000 fold (47).  AMPK that 
is not phosphorylated at α1 Thr172 displays negligible kinase activity (48).  Therefore, 
this phosphorylation/dephosphorylation mechanism plays a major role in regulating 
AMPK activation/inactivation.   
In mammalian cells the three predominant upstream kinases responsible for 
phosphorylation of Thr172 are liver kinase B1 (LKB1), Ca2+ /calmodulin-dependent 
protein kinase kinase β (CaMKKβ), and transforming growth factor (TGF)-β-activated 
kinase-1 (Tak1 kinase) (42).  LKB1 is constitutively active in cells, and the molecular 
mechanism of LKB1 phosphorylation of AMPK is unclear (49).  The role of LKB1 in 
activating AMPK has been demonstrated via different methods.  LKB1 activation of 
AMPK in vitro was demonstrated by immunoprecipitation and kinase activity assays, and 
pharmaceutical activators failed to induce AMPK kinase activity in LKB1-deficient 
murine embryonic fibroblasts (MEFs) (50).  Several AMPK-related kinase activities are 
stimulated by LKB1 (49), and blockage of LKB1 activity in cells abolishes AMPK 
activation in response to different stimuli (51).  In addition to LKB1, CaMKKβ is 
considered another important AMPK upstream kinase in many cell types in different 




ionomycin, which increases intracellular Ca2+, led to increased phosphorylation of 
AMPKα Thr172, a response inhibited by the treatment with the CaMKKβ inhibitor STO-
609 in HeLa and A549 cells (53).  Increased AMPK activity was observed in mammalian 
cells with overexpression of CaMKKβ (54), whereas treatment with CaMKKβ siRNA or 
pharmaceutical inhibitors abolished AMPK activation (54, 55).  Other studies supporting 
CaMKKβ-dependent AMPK activation in response to different agents were also reported 
in cell types including endothelial cells (56), T cells (57), and neurons (58).  Tak1 kinase 
belongs to the mitogen-activated protein 3-kinase family and was recently suggested to 
regulate AMPK activities (59).  Recombinant Tak1, fused to the activation domain of its 
binding partner TAB1, was able to induce AMPKα Thr172 phosphorylation in vitro and 
elevated Thr172 phosphorylation was detected in HeLa cells transfected with plasmids to 
transiently express Tak1 or TAB1 (59).  Loss of Tak1 expression in MEFs blocked 
AMPKα Thr172 phosphorylation and activity induced by the three pharmaceutical 
activators tested (oligomycin, metformin, and AICAR) (60).  However, the ability of 
Tak1 kinase to act an upstream kinase to regulate AMPK activation was challenged by a 
study by Kim et al. (61).  In this study a direct interaction between Tak1 and AMPK was 
observed in THP-1 cells by co-immunoprecipitation, and both LPS-induced Tak1-Thr187 
phosphorylation and Tak1 activity were reduced in AMPKα1 siRNA-containing 
lentiviruses transfected THP-1 cells, proposing an upstream role of AMPK to regulate 
Tak1 activity (61).  The role of Tak1 as an upstream kinase of AMPK activation is 
therefore controversial and requires further investigation.   
The identification of phosphatases that dephosphorylate the AMPKα subunit and 




AMPK/ADP-binding to the AMPKγ CBS3 domain confers protection against AMPK 
dephosphorylation (44), it seems likely the phosphatases involved in the 
dephosphorylation of AMPK are stimuli and/or cell type-dependent.  In vitro studies have 
identified the ability to dephosphorylate AMPKα-Thr172 of members in the protein 
phosphatase 1 (PP1) and protein phosphatase 2A (PP2A), both from PPP (phosphoprotein 
phosphatase) family (35) and protein phosphatase 2C (PP2C), PPM (metal-dependent 
protein phosphatase) family (46), while specific inhibition of the PPP family by okadaic 
acid did not affect AMPK activity in rat hepatocytes (62, 63), suggesting that AMPK 
dephosphorylation is catalyzed primarily by one or more members of the PPM family.  
However, inhibition of the PPP family phosphatase activities by siRNA knockdown is 
also effective to block glucose-induced AMPKα-Thr172 dephosphorylation in murine 
pancreatic β cell line (64).  Therefore, the identification of phosphatases involved in cell-
type and/or stimulus-dependent AMPK dephosphorylation effect is ongoing.   
 A wide range of physiological stresses regulate AMPK activity, for example 
muscle contraction, glucose deprivation, oxidative stresses, treatment with heat shock 
proteins, etc. (65).  A variety of agents are recognized as AMPK activators and become 
pharmacological treatments for many diseases like type 2 diabetes (T2D), obesity, cancer, 
and atherosclerosis (10, 66, 67).  These activators include 5-aminoimidazole-4-
carboxamide riboside (AICAR) (68), a nucleoside converted within the cell to an AMP 
mimetic, metformin (69) and thiazolidinediones (TZDs, such as rosiglitazone), both 
drugs used to treat T2D and atherosclerosis (70).  Different mechanisms were proposed 
for the action of those activators including increased AMP and/or ADP levels, activation 




accumulation of cellular cAMP (10).  Understanding the pharmacological mechanisms of 
these AMPK-activating drugs to treat disease still needs investigation, as both AMPK-
dependent (68) and AMPK-independent (71) effects of these drugs were reported.  
 
Notably hormones and cytokines are also reported to regulate AMPK activity (72-
75).  Adiponectin and leptin are both hormones secreted by adipose tissue that play 
important roles in regulating energy homeostasis and glucose and lipid metabolism.  
AMPK can be activated by stimulation with adiponectin and this effect is responsible for 
adiponectin induced fatty-acid oxidation and glucose uptake in both liver and muscle 
cells (76).  Leptin also induces fatty acid oxidation and glucose uptake in muscle, and 
leptin activation of AMPK is required for this action (77).  In leukocytes, stimulation 
with adiponectin resulted in increased production of antiinflammatory cytokine IL-10 
(78), similar to the effect of AMPK activation in macrophages that we reported 
previously (14).   Cytokines such as TNFα and IL-6 are also reported to modulate AMPK 
activity.  Chronic treatment with TNFα leads to suppression of AMPK activation in 
muscle cells via transcriptional up-regulation of PP2C (79).  Stimulation with IL-6 
rapidly increased AMPK activation in myotubes (80), and this enhancement of AMPK 
activity by IL-6 treatment was also observed in muscle and adipocytes (81).   
The published research in our lab revealed a key regulatory role of AMPK in 
macrophage phenotypic activation in response to physiological stimuli with pro- or anti- 
inflammatory functions (14).  In this research, AMPKα1 was shown to be the major 
isoform expressed in macrophages.  Phosphorylation on AMPKα-Thr172 residue was 




















Figure 2. AMPK is activated by antiinflammatory stimuli and suppresses the LPS-
induced NF-κB pathway in macrophages.  Stimulation with IL-10 activates AMPK.  In 
macrophages stimulated with LPS, AMPK suppresses proinflammatory cytokine 
production by inhibition of NF-κB pathway, whereas it promotes antiinflammatory 









antiinflammatory cytokines, whereas stimulation with TNFα or LPS reduced AMPK 
activation in macrophages.  Forced expression of CA-AMPKα1 in macrophages led to 
increased IL-10 production while decreased proinflammatory cytokine production in 
response to LPS, whereas forced expression of DN-AMPKα1 led to the opposite effect in 
macrophages.  This ability of activated AMPK to promote macrophage antiinflammatory 
functions is supported by mechanistic studies, which showed that the LPS-induced NF-
κB signaling pathway activation was greatly suppressed in the CA-AMPKα1 
macrophages while the opposite occurred in the DN-AMPKα1 macrophages.  This study 
promoted the theory that the pro- or anti- inflammatory physiological stimuli in the 
microenvironment are able to antagonize or promote AMPK activation, leading to 
enhanced or suppressed macrophage inflammatory function, respectively (Fig. 2).  This 
previous study provided the theoretical foundation of this Ph.D. dissertation research 
investigating the underlying mechanism of AMPK regulation of IL-10-induced immune 
suppressive signaling pathways, which lead to macrophage activation towards an 
antiinflammatory state.    
 
AMPK in metabolic syndromes  
The exclusive role of AMPK in maintaining energy homeostasis over the whole 
body has implications for its role in metabolic syndromes such as insulin resistance, T2D, 
cardiovascular disease, and fatty liver disease.  To sustain metabolism, the intracellular 
ATP concentration must be regulated within an appropriate range in the body at both 
subcellular and systemic levels.  As a tissue that constantly requires significant variation 




of metabolic disorders (82).  Several beneficial drugs such as polyphenols (83) and 
berberine (84) used to treat metabolic disorders stimulate AMPK activity in skeletal 
muscle.  Improved AMPK activity is responsible for PPARγ coactivator-1α (PGC-1α)/ 
glucose transporter 4 (GLUT-4) activation/expression in muscle cells to promote glucose 
uptake and fatty acid oxidation (85), effects that contribute to improvements in insulin 
sensitivity and obesity.   
The AMPK-mediated gene regulation related to glucose uptake and lipid 
oxidation is also seen in liver, an organ that plays pivotal role in the control of whole 
body metabolism of energy nutrients (86).  The first two AMPK downstream substrates 
identified, ACC and HMG-CoA reductase, are key enzymes in the regulation of fatty acid 
and cholesterol synthesis, respectively, in the liver.  Hepatic AMPK can be activated by 
physiological stimuli such as exercise and nutrient deprivation, physiopathological 
situations such as prolonged starvation or chronic alcohol consumption, and 
pharmacological drugs such as metformin and TZDs (70, 87).  Activation of hepatic 
AMPK leads to inhibition of ACC and enhanced fatty acid oxidation (88), inhibition of 
HMG-CoA reductase and reduced cholesterol synthesis (89), and inhibition of the  
TSC2/mTOR pathway and decreased protein synthesis (90).  Meanwhile, hepatic AMPK 
also suppresses the expression of glycolytic and lipogenic genes such as liver-type 
pyruvate kinase (L-PK), fatty acid synthase (FAS) (91), sterol regulatory element-binding 
protein-1c (SREBP-1c), and carbohydrate response element-binding protein (ChREBP) 
(92), as well as gluconeogenic genes such as phosphoenolpyruvate carboxykinase 
(PEPCK) and glucose-6-phosphatase (G6Pase) (92).  Increased hepatic glucose 




metabolic pathway for glucose output in liver, plays a beneficial role in improving overall 
glycemic control in T2D.  Treatment with AMPK activator abolishes hyperglycemia in 
diabetic ob/ob mice (92).  Hepatic AMPK therefore provides a valuable therapeutic target 
for the management of metabolic hepatic disorders linked to T2D and obesity. 
Adipose tissue is composed of adipocytes, endothelial cells, fibroblasts and 
macrophages.  It plays a key role in energy storage and is well recognized as an 
endocrine organ secreting the anorexigenic cytokine, leptin, and the insulin-sensitizing 
hormone, adiponectin (75). During exercise, fasting and in the presence of hypoglycemic 
drugs, AMPK can be activated in adipose tissue.  Leptin and adiponectin are both 
activators of AMPK (76, 77, 93, 94).  As in the liver, activation of AMPK in adipose 
tissue suppresses ACC activity and the expression of lipogenic genes thus favors local 
fatty acid oxidation while repressing lipogenic fluxes.  In addition, activation of AMPK 
leads to limitation of lipolysis, a process that the adipose tissue employs to break down 
the triglycerides through the lipolytic pathway during fasting to provide fatty acids and 
glycerol as fuels for peripheral tissues (95).  Treatment with the AMPK activator AICAR 
inhibited the secretion of TNFα and IL-6 in adipose tissue (96, 97).  To summarize, 
adipose tissue AMPK tends to enhance local fatty acid oxidation while inhibiting fatty 
acid and triglyceride synthesis and lipolysis to limit fatty acid efflux from adipocytes to 
the plasma.  This AMPK effect is extremely beneficial in insulin-resistant states such as 







AMPK in inflammation 
It is known that metabolic syndromes, particularly obesity, T2D, fatty liver 
disease and atherosclerosis, are associated with chronic inflammation (98).  The ability to 
withstand starvation and the capacity to mount an effective immune response to 
pathogens are among the most fundamental requirements for species survival.  The two 
systems, metabolism and inflammation, are highly integrated and the proper function of 
each is dependent on the other.  Evolutionarily, the functional units that control key 
metabolic and immune functions in higher organisms have evolved from common 
ancestral structures such as the Drosophila fat body, a structure found in lower organism 
Drosophila melanogaster which incorporates the mammalian homologues of the liver 
and the hematopoietic and immune systems (98, 99).  The association between 
metabolism and inflammation is also evident in metabolic important tissues of higher 
organisms, for example the liver and adipose tissue where macrophages reside along with 
hepatocytes and adipocytes.  The immune effector cell macrophages and the metabolic 
important cell adipocytes show evidence of coordination and coevolution.  Both of these 
two cell types share common functions such as cytokine secretion and responsiveness to 
LPS (100).  This coevolutionary relationship is also supported by the evidence that a 
wide range of overlapping gene expression is found between macrophages and 
adipocytes, and many adipocyte-specific metabolic and other genes are upregulated 
during the transformation of macrophages into foam cells (101).  Given the critical role 
of AMPK in metabolic syndromes, it is not surprising the regulation of inflammatory 
responses also requires AMPK activity.   




autoimmune encephalomyelitis (EAE) (102) and colitis (103), both disease models 
associated with chronic inflammation.  Metformin, an effective anti-diabetic drug and 
AMPK activator, confers antiinflammatory features in impaired glucose tolerance (IGT) 
patients (104), IL-1β treated human vascular wall cells (105), LPS or oxidized LDL 
treated human monocytes (106), and endotoxin-induced uveitis rat model (107).  Chronic 
treatment with TNFα leads to suppression of AMPK activation in muscle cells via 
transcriptional up-regulation of PP2C, an effect that is associated with downregulated 
fatty acid oxidation (79), and neutralization of TNFα leads to elevated AMPK activity in 
a murine obese model.  This study provides evidence supporting an AMPK-regulated 
mechanism to link inflammation and defective fatty acid metabolism in obesity.   
Our report in 2008 was the first investigation of AMPK activity in immune cells 
(14).  Macrophages are important players in both innate and adaptive immune responses.  
The accumulation of macrophages in adipose tissue in an inflammatory state is a 
hallmark of obesity-induced insulin resistance.  Our study showed that AMPK activation 
is directly triggered by antiinflammatory stimuli such as IL-10, TGFβ, and IL-4, whereas 
it is suppressed by proinflammatory stimuli such as LPS and TNFα in macrophages.  
Activated AMPK then acts as a key regulator to promote macrophage antiinflammatory 
functions via stimulation of the Akt/CREB pathway and inhibition of the IKK/IκB/NF-
κB pathway (14).  A number of studies then emerged after our initial findings to further 
demonstrate an important regulatory role of AMPK in macrophages (108, 109), dendritic 
cells (DCs) (15, 110), and T cells (111-113).  Macrophages deficient in AMPKβ1 
expression displayed increased levels of diacylglycerol and markers of inflammation, and 




resistance in adipose and hepatic tissue in mice fed on high fat diet (HFD) (108), 
revealing a protective role of myeloid AMPK against inflammation and insulin resistance 
during obesity.  AMPK activity is reduced in macrophages treated with fatty acids and 
HFD (109).  In an adipocyte/macrophage co-culture system, inactivation of AMPKα1 in 
macrophages resulted in reduced insulin signaling in adipocytes.  This research also 
showed that macrophage AMPKα1 negatively regulates the inflammatory response 
caused by exposure to free fatty acids, LPS or diet-induced obesity by inhibiting NF-κB 
signaling in via SIRT1 deacetylation of the NF-κB p65 subunit (109).  In addition to the 
key regulatory role of AMPK in macrophage antiinflammatory functions (14), we also 
reported a positive role of AMPK to suppress CD40-mediated inflammatory responses in 
DCs (15).  AMPK-deficiency in both macrophages and DCs lead to increased IL-6 and 
TNFα production, whereas IL-10 production was decreased in response to LPS 
stimulation.  The antigen-induced Th1 and Th17 responses were enhanced in T cells co-
cultured with AMPKα1-deficient macrophages and DCs.  Upon treatment of CD40 
ligand, CD145, stimulation, AMPKα1-deficiency was shown to limit Akt/CREB pathway 
activation while enhancing NF-κB and MAPK pathways therefore enhancing CD40-
induced proinflammatory responses in DCs (15).  LPS stimulation was shown to reduce 
AMPK activation in DCs and this effect was accompanied by increased cellular glucose 
consumption (110).  In addition to our findings that AMPK-deficiency in both antigen 
presenting cells (APCs) and T cells greatly enhanced Th1 and Th17 responses, AMPK is 
also shown to improve T cell viability in the absence of survival signals such as IL-2, and 
to suppress GLUT-1 expression and to limit glycolysis in T cells (111).  Significantly, 




(Teff), and treatment with metformin improves Treg frequency (112).  Most recently, 
AMPKα1 expression was found essential for generation of CD8+ T cell memory (113).  
 
In contrast to the long road discovering AMPK functions in metabolic systems 
since the 1970s, the understanding of AMPK function in immune responses is relatively 
nascent, but quickly developing.  Research in our lab has been conducted with keen 
interest in exploring mediators of immune cell functional plasticity.  During the discovery 
of fatty acid binding protein (FABP) regulation of macrophage phenotype the significant 
role of AMPK was noticed.  Investigation of AMPK regulation of immune cell functions 
including macrophages, DCs and T cells have been developed in our lab and important 
roles of AMPK in the regulation of immune responses has been revealed.  The underlying 
mechanisms responsible for these AMPK-mediated effects in different immune cells need 
to be further defined.  Herein, we provide evidence to support an important role of 
macrophage expressed AMPK in the expression of atheroprotective proteins and 
demonstrate a key role of AMPK to integrate and regulate IL-10-induced signaling 
pathways that lead to functional reprogramming of macrophage functions towards an 
antiinflammatory direction.  These studies underscore the value of AMPK as a 
therapeutic target for chronic inflammation-associated diseases such as atherosclerosis, 











Atherosclerosis is commonly associated with metabolic syndromes.  Statistics in 
2010 implicate that atherosclerosis is the leading cause of death and morbidity in 
developed countries and is likely soon to attain this status worldwide (114). 
Atherosclerosis is characterized by a lipid metabolic imbalance that results in 
accumulation of lipids and fibrous elements at the artery wall.  This process leads to a 
chronic inflammatory process and to the development of complex lesions, or plaques, that 
protrude into the arterial lumen and induce acute clinical complications of myocardial 
infarction and stroke (115).  In the body, dietary and endogenous cholesterol is carried 
and transported by several lipoprotein particles including chylomicrons, very low-density 
lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins 
(HDL).  The majority of serum cholesterol is carried by LDL, which can be transformed 
from VLDL by removal of the triglyceride content from the particle.  LDL is subject to 
oxidative modifications in the subendothelial space, and progresses from minimally 




within LDL droplets can be internalized by the peripheral cells expressing LDL receptor 
(LDLR) via receptor recognition, whereas modified/oxidized LDL particles can only be 
recognized by a group of scavenger receptors such as SR-A and CD36.  While high LDL 
cholesterol level is associated with high risk of cardiovascular disease, lack of LDLR 
expression in mice could significantly exacerbate plasma cholesterol level induced by 
HFD and result in massive hypercholesterolemia leading to extensive atherosclerotic 
disease (117).  Accumulation of modified LDL in the artery wall results in endothelial 
cell expression of adhesion molecules like VCAM-1 and monocyte-attractive chemokine 
like MCP-1.  Circulating monocytes are attracted to the artery wall directly by ox-LDL 
and by endothelial-secreted MCP-1 and attach to the endothelial layer via the adhesion 
molecules.  The adherent monocytes then migrate into the subendothelial space and 
differentiate into macrophages.  At the intima, macrophages take up ox-LDL via 
scavenger receptors and transform to foam cells.  This process is so called “fatty streak 
lesion” formation, and initiates the first steps of atherosclerosis.  The development of 
lesion progression is mediated by a chronic state of inflammation created by interactions 
between macrophage-derived foam cells and T cells.  Cytokines secreted by lymphocytes 
and macrophages exert both pro- and anti- atherogenic effects on each of the cellular 
elements of the vessel wall.  Smooth muscle cells (SMCs) migrate from the medial 
portion of the arterial wall to the lesion where they proliferate and secrete extracellular 
matrix (ECM) proteins that form a fibrous plaque.  With growing burden of the lesion, 
macrophage- and SMC-derived foam cells undergo necrotic death and release the lipid-
rich cell contents to the necrotic core of the lesion.  The lesions continue to grow by the 




protein production and the accumulation of extracellular lipid.  During this process, 
macrophage secretion of matrix metalloproteinases (MMPs) and neovascularization 
contribute to weakening of the fibrous plaque.  Eventually, the plaque ruptures and 
exposes blood components to tissue factor, which initiates coagulation, the recruitment of 
platelets, and the formation of a thrombus, resulting in myocardial infarction or stroke 
(115, 118). 
 
MACROPHAGES AND AMPK IN ATHEROSCLEROSIS 
Macrophages in atherosclerosis 
Atherosclerosis was once considered to be a cholesterol storage disease 
characterized by the collection of cholesterol and thrombotic debris in the artery wall.   
With the identification of abundant monocyte-derived macrophages in atherosclerotic 
plaques, and the gradual recognition of their importance in atherogenesis, macrophage-
mediated innate and adaptive immunity provided modern insights to the research of 
atherosclerosis as a complex chronic inflammatory disease (118-122).   
Macrophages play important roles in all steps of atherosclerosis progression, from 
lesion formation to plaque destabilization.  A hallmark of atherosclerosis is the 
transformation from monocyte-derived macrophages to lipid-laden foam cells in the 
subendothelial intima.  Although macrophage take-up of lipoproteins is initially 
beneficial, lack of negative feedback mechanisms results in accumulation of lipids within 
those macrophages.  This leads to dysregulation of lipid metabolism and alters the 
immune features of macrophages, both in proliferative functions and inflammatory 




macrophages continue to establish a chronic inflammatory response with the participation 
of other local or recruited immune cells to the lesion by secreting proinflammatory 
mediators including chemokine, cytokines, reactive oxygen and nitrogen species, and 
matrix-degrading proteases.  Eventually the death of macrophages causes the release of 
the tissue factor- and lipid-rich contents which leads to the formation of necrotic core, a 
key component of unstable plaques.  The rupture of the unstable plaque is the final cause 
of myocardial infarction and stroke (17, 125).   
Although many immune cell types exhibit heterogeneity during atherosclerosis 
such as monocytes and DCs, the central role of macrophage heterogeneity and functional 
phenotypic change has been highlighted in a growing body of evidence (17, 125, 126).   
A broad range of macrophage heterogeneity is found in atherosclerotic lesions at different 
plaque development stages (127), with proinflammatory macrophage phenotypes found 
to be enriched in progressing plaques and antiinflammatory macrophage phenotypes 
found to be enriched in regressing plaques.  Moreover, phenotypic changes from an 
antiatherogenic “M2-like” state of activation to a proatherogenic “M1-like” state of 
activation is observed during atherosclerosis progression (128).  We previously described 
a remarkable macrophage plasticity to be differentially activated by microenvironmental 
factors (1, 7, 8).  The diverse plaque-associated environmental signals, even with 
opposing immune features, may play critical role in directing macrophage polarization 
during lesion development.  Indeed, a high level of IL-4 in early stage lesions, and a high 
level of IFNγ in late stage lesions, is found to associate with the phenotypic switch from 
“M2-like” activation state to “M1-like” activation state of macrophages during 




activation as well as induce unique gene expression patterns (129, 130).  These studies 
suggest the environmental factors during atherosclerosis lesion progression contribute 
siginificantly to macrophage activation and phenotypic polarization, therefore modulating 
plaque development.   
Given the significance of macrophages, many regulators of macrophage 
cholesterol trafficking and macrophage functional polarization have been identified as 
therapeutic targets to treat atherosclerosis.  These targets include growth/differentiation 
factors such as macrophage colony-stimulating factor M-CSF (125), cytokines such as 
IL-10 (131-133), lipid chaperones such as fatty acid binding proteins (FABPs) (134), 
transcription factors such as peroxisome proliferator activated receptors (PPARs) and 
liver X recepters (LXRs) and subsequent genes including apolipoprotein E (apoE) and 
ATP-binding cassette transporter A1 (ABCA1) (135).   Most recently AMPK is also 
suggested to play atheroprotective roles (136), although these studies have focused on 
endothelial inflammation and the endogenous AMPK activation in macrophages received 
less attention in atherosclerosis research. 
 
Fatty acid-binding proteins (FABPs) in atherosclerosis 
FABPs comprise a family of homologous cytosolic proteins with distinct patterns 
of tissue expression. The capability of FABPs to bind hydrophobic compounds and 
shuttle them between cytoplasmic compartments and enzyme systems within the cell has 
implicated FABPs as upstream modulators of many lipid signaling cascades (137-140).  
Studies on FABP-deficient mouse models reveal a strikingly protective role of FABP-




atherosclerosis (134, 141).  A-FABP, also known as aP2 and Adipocyte Lipid Binding 
Protein (ALBP), is expressed by adipose tissue, adipogenic cell lines, and macrophages.  
A-FABP-deficiency provides remarkable protection against atherosclerosis in apoE-
deficient models of atherosclerosis, and this effect of A-FABP is predominantly related to 
its actions in the macrophage (142, 143).  Likewise, treatment with A-FABP inhibitors 
specifically targeting macrophages protects mice against severe atherosclerosis (144).   
The collaborative work between Suttles’ lab and Hotamisligil’s lab provided the 
underlying mechanism of A-FABP to control macrophage cholesterol trafficking and 
inflammatory activity via impairment of PPARγ activity that leads to inhibition of CD36 
and ABCA1-mediated pathways and enhancement of IKK/NF-κB pathway, respectively 
(145).   
Notably, A-FABP binds to a variety of metabolites including compounds that act 
as ligands for PPARγ  (146, 147).  Although there are reports of FABPs shuttling PPAR 
ligands to the nucleus in non-macrophage cell types (148-150), our previous observation 
of elevated PPARγ activity in A-FABP-deficient macrophages suggests that in 
macrophages, FABPs act to sequester PPARγ ligands in the cytosol, thus preventing their 
migration to the nucleus.  When A-FABP expression is absent, lipid ligands are free to 
interact with nuclear receptors, as well as other targets, including IKK (145).  This 
speculation is supported by the Suttles lab’s unpublished confocal microscopy data 
showing that a PPARγ ligand, 13-HODE, is sequestered in the cytosol of wild-type 
macrophages whereas is present in the nucleus of A-FABP-deficient macrophages (Fig. 














Figure 3. Presence of FABPs prevents nuclear localization of 13-HODE.  (A), 13-HODE 
(10µM) (green) was restricted to the cytoplasm of macrophages in the presence of A-
FABP expression, but was able to enter the nucleus in A-FABP-deficient macrophages 
















Peroxisome proliferator activated receptor γ (PPARγ) in atherosclerosis 
PPARγ is expressed in macrophages and belongs to the PPAR family of nuclear 
receptors, which are ligand-activated transcription factors that function as fatty acid 
sensors to regulate glucose and lipid metabolism (151, 152).  Studies in vitro 
demonstrated the role of PPARγ to promote cholesterol trafficking in macrophages via 
transcriptional induction of genes encoding proteins involved in cholesterol trafficking 
including the scavenger receptor CD36 (153), LXRα and ABCA1 (154).  Treatment with 
PPAR agonists in vivo exhibit beneficial effects in atherosclerosis animal models (135).   
Expression of PPARγ can be induced by IL-4 stimulation in macrophages (155), and 
activation of PPARγ promotes macrophage activation towards an antiinflammatory state 
associated with elevated expression of Arg 1, MR, and the antiinflammatory cytokine IL-
10 (156-158)  while it suppresses activation of proinflammatory pathways and gene 
expression (155, 159).   
 
Interleukin 10 (IL-10) in atherosclerosis 
IL-10 is a potent immunosuppressive cytokine produced by Th2-type T cells, B 
cells, monocytes, and macrophages that systemically limits excessive inflammation and 
controls inflammatory disease progression including atherosclerosis (160, 161).  It is 
produced in atherosclerotic lesions and correlates with diminished expression of 
inflammatory mediators within the lesion and vessel wall (162-164).   IL-10-deficient 
C57BL/6 mice fed on an atherogenic cholate-containing diet develop early 
atherosclerotic lesions, characterized by increased lipid accumulation, increased 




(131, 165).  The similar atheroprotective property of IL-10 is demonstrated with IL-10-/- 
apoE-/- mice fed a chow diet (166).  Consistent with this protective role of IL-10 in 
atherosclerosis, overexpression of IL-10 using the human IL-2 promoter or by adenoviral 
gene transfection resulted in effective prevention of atherosclerosis development (165, 
167).  Leukocyte-derived IL-10 is crucial in the prevention of atherosclerotic lesion 
development as it influences leukocyte functions as well as modulates systemic immune 
response thus influences plaque composition (168).  Most recently, a series of studies by 
Han et al., established a critical role of IL-10 in promoting cholesterol trafficking in 
macrophages treated with modified LDL by promoting PPARγ-mediated atheroprotective 
gene productions whereas inhibiting proinflammatory gene expression (132), and 
macrophage specific overexpression of IL-10 in mice led to reduced atherosclerosis 
development (133), suggesting an important role of IL-10-regulated macrophage function 
in regulating atherosclerosis progression.  All the studies analyzing the role of IL-10 in 
murine atherosclerosis models demonstrated that the regulation of balance between 
proinflammatory and antiinflammatory cytokines is decisive for disease development and 
progression (161).  Therefore, research seeking for the regulators of this balance, 
especially in macrophages, is extremely promising as a source of new therapeutic targets 
to treat atherosclerosis. 
 
AMPK in atherosclerosis 
Our research has established a key regulatory role of AMPK in modulating 
macrophage polarization in response to pro- or anti- inflammatory stimuli that 











Figure 4. FABP-deficient macrophages express elevated AMPK activity.  Macrophages 
with deficient expression of A-FABP, E-FABP, or both A- and E-FABP show significantly 



















proinflammatory and antiinflammatory cytokines (14).  Therefore, the AMPK expression 
in macrophages may play important roles in atherosclerosis.  In support of this 
hypothesis, the atheroprotective role of AMPK has been suggested in recent studies based 
on the significant role of AMPK in regulating both metabolic fatty acid oxidation 
pathways and inflammatory pathways (18, 19, 66, 136).  Many atheroprotective agents 
are proved to be potent AMPK activators such as AICAR, metformin, TZDs, statins, and 
adiponectin.  However, the protective role of AMPK has not been investigated until 
recent, and most of the studies concerning this topic focus on the AMPK regulation of 
metabolic processes in non-immune cells such as in endothelial cells and SMCs.  The 
underlying mechanism of this AMPK atheroprotective effect is not well demonstrated 
and the role of macrophage expressed-AMPK in the regulation of atherosclerosis 
progression has not been reported so far.   
 
During the investigation of FABP regulation of macrophage functions (145), we 
found a striking effect that FABP-deficient macrophages display greatly enhanced 
PPARγ activity accompanied by elevated IL-10 production, and significantly enhanced 
AMPK activity (Fig. 4).  We have also shown that FABPs can antagonize PPARγ activity 
by holding its ligands within the cytosol (Fig. 3).  PPARγ is reported to promote 
antiinflammatory responses in macrophages including the induction of IL-10 expression 
(158).  IL-10 activates AMPK in macrophages in a time-dependent manner (14), AMPK 
then act as a counter regulator of macrophage inflammatory responses.  Interestingly, 
AMPK has also been implicated in the activation of PPARs, in part due to upregulation 




macrophage-expressed AMPK plays an important role in cardiovascular disease and that 
the systemic protective effect of AMPK activators includes their influence on 
macrophage AMPK activity.  We previously observed greatly increased macrophage 
expression of FABP in mice feed on HFD; here we provide evidence to support a FABP/ 
PPARγ pathway that leads to increased IL-10 production resulting in increased AMPK 
activation, which in turn, promotes PPARγ activity and IL-10 signaling in macrophages 
and mantains macrophage polarization towards an antiinflammatory, antiatherogenic 




MATERIAL AND METHODS 
 
Mice  
Macrophage-specific constitutively active (CA)-AMPKα1 and dominant negative (DN)-
AMPKα1 transgenic mice were provided by Dr. DeBroski Herbert, Division of 
Immunology, University of Cincinnati College of Medicine.  These mice were crossbred 
with LDLR-/- mice to generate macrophage-specific CA/DN-AMPKα1/LDLR-/- mice.  
C56BL/6J mice and LDLR-/- were purchased from The Jackson Laboratories.  AMPKα1 
deficient (AMPKα1-/-) mice were generated as previously described (170).  C57BL/6J 
mice were purchased from the Jackson Laboratory.  These mice were bred and 
maintained in the Research Resources Facility, University of Louisville. All animal care 
and experimental procedures were approved by the Institutional Animal Care and Use 
Committee, University of Louisville.   
 
High Fat Diet procedure 
High fat diet (60% kcal from fat, product number D12492) food was purchased from 
Research Diets, Inc.  After being weaned, macrophage-specific CA-AMPKα1 and DN-
AMPKα1 transgenic mice with C56BL/6J control mice were placed on the diet for 80 
days (10 mice per group).  Whole body weight of individual mouse was weighted every 
two days.  Fat tissue was isolated from different parts of the body and weighted before fat 




Fat associated macrophage (FAM) isolation 
Fat pads were isolated from animal and weighted before fat associated macrophage 
(FAM) isolation.  The fat tissue was then placed into 10 cm petri dish with PBS + 2% 
FBS.  Fatty tissue was cut into small pieces and collected into a 50ml tube and PBS + 2% 
FBS was added to get a final volume of 30 ml.  Samples were centrifuged at 500 g, 4°C 
for 5 minutes to remove the red blood cells.  The floating tissue was transferred to a new 
tube and collagenase was added for 30-60 minutes at 37°C, depending on the tissue 
volume.  The tube was lightly vortexed every 5-10 minutes for contact.  The contents 
were filtered through a 100um fliter into a 50mL conical tube. Samples were washed 3 
times with PBS + 2% FBS by centrifugation at 500g, 4°C for 5 min between washes. 
After the final wash, the floating tissue and buffer was removed and the SVT pellet was 
resuspended in fresh buffer.  Single-cell suspension was achieved by gentle pipetting. 
Gey’s solution was added for 5 min to remove red blood cells.  Samples were then 
washed 3 times with PBS + 2% FBS by centrifugation at 500g, 4°C for 5 min between 
washes.  Cells were counted for FAM isolation.  FAM were isolated by positive selection 
with anti-CD11b (Mac-1) magnetic beads (Miltenyi Biotec). A purity of  > 95% CD11b+ 
cells was confirmed by flow cytometry.  
 
Reagents 
LPS (Escherichia coli serotype O111:B4) was purchased from Sigma-Aldrich.  
Recombinant mouse IL-10 was purchased from R&D Systems.  Purified NA/LE Rat 
Anti-Mouse IL-10 neutralization Ab. was purchased from BD PharmingenTM.  15-deoxy-




Rosiglitazone, and GW9662 were purchased from Cayman Chemical (Ann Arbor, MI).  
Western blot detection of specific proteins used the following primary Abs: anti-A-FABP, 
anti-E-FABP (R&D Systems), anti-phospho-AMPKα (Thr172), anti-AMPKα (Cell 
Signaling), anti-β-actin (Sigma-Aldrich), and HRP-conjugated secondary Ab (Jackson 
ImmunoResearch Laboratories).  
 
Cells 
Bone marrow-derived macrophages (BMDM) were generated from C57BL/6J mice 
following the protocol previously described (171).  CA-AMPKα1 and DN-AMPKα1 
macrophage stable transfected cell lines were generated following the protocol previously 
described (14).  Cell culture were maintained in incubators set to 37°C and 5% CO2.  For 
stimuli/reagents used in individual experiments, cells were harvested into a 24-well cell 
culture plate (1 x 106 cells/well) and rested overnight in RPMI medium supplemented 
with 5% FBS, 10ml HEPES Buffer (Sigma), and 1ml gentamycin (Atlanta Biologicals) 
(referred as R5 medium) prior to stimulus.  The cells were quickly rinsed with pre-
warmed DPBS supplemented with 2% FBS before lyse.  Kupffer cells were isolated from 
mouse liver by preparing single cell suspension according to gentle MACS protocol 




Bone marrow-derived macrophages were transfected with 0.5 μg AMPKα1 or PPARγ 




Scientific) using NucleofectorTM Kits according to the corresponding AmaxaTM 
Optimized Protocols (Lonza). Following NucleofectionTM, the macrophages were plated 
in 12-well plates in RPMI 1640 (HyClone) medium containing 20% FBS (Atlanta 
Biologicals), 10 mM HEPES, and 10 μg/ml gentamicin.  The cells were analyzed 24 h or 
48 h post-transfection.  
 
Real-time RT-PCR analysis 
mMACsTM One-step cDNA Kit (Miltenyi Biotech) were used for RNA isolation and 
cDNA synthesis. cDNAs were amplified in a 20 μl reaction volume containing SYBR 
Green (New England Biolabs) and analyzed using a DNA Opticon 2 Monitor (MJ 
Research).  All the gene mRNA expression levels (abca1, apoe, socs3, socs1, nr1h3, 
arg1, il-10, tgfb, tnfa, il-6, and il-12b) were analyzed by Quantitect Primer Assays 
(Qiagen).  The cDNA concentrations in each sample were normalized using transcripts 
for β-actin.  The relative expression software tool (REST©) was used to quantify mRNA 
expression (172).   
 
Western blot analysis 
Whole cell lysates were generated by lysis with a buffer containing 125 mM Tris (pH 
6.8), 2% SDS, 20% glycerol, 100 μM PMSF, protease inhibitor mixture (Promega), and 
HALTTM phosphatase inhibitor cocktail (Thermo Scientific).  Total protein content of the 
samples was assessed by BCA protein assay (Pierce).  Equal amounts of protein were 
separated on 10% Criterion gels (Bio-Rad) by SDS-PAGE.  Medium and high molecular 




Trans-Blot® TurboTM Nitrocellulose Transfer Pack and Trans-Blot®TurboTM transfer 
system (Bio-Rad).  Low molecular weight proteins (< 55kDa) were transferred to 
nitrocellulose membranes (Hybond; Amersham Biosciences) using a Trans-Blot SD 
semidry electrophoretic transfer cell (Bio-Rad).  Ab-bound proteins were detected using 
an ECL Western blotting analysis system (Amersham Corp.), and the membranes were 
exposed to SRX-101A film (Konica Minolta).  Densitometry analysis was performed 
using the UN-SCAN-IT gel (version 6.1) software.  
 
ELISA 
Following stimulation in 24-well plates, supernatants were collected into 96-well plates 
and assayed by ELISA using OptEIATM sets (BD Biosciences Pharmingen) according to 
the manufacturer’s instructions.  Analysis was performed using an E-max precision micro 
plate reader (Molecular Devices). 
 
Statistical Analysis  
Statistical significance between groups was calculated with an unpaired Student’s t test, 












Generation of macrophage-specific CA-AMPKα1 and DN-AMPKα1 mice 
Our lab previously constructed stable transfected macrophage cell lines with 
expression of either CA-AMPKα1 or DN-AMPKα1 by nucleotransfection (14).  The CA-
AMPKα1 containing constructs encode an α1 subunit with a polypeptide truncated at 
residue 312 so it no longer associates with the β and γ subunits but retains significant 
kinase activity.  The DN-AMPKα1 containing constructs encode an α1 subunit with 
mutation of aspartate 157 to alanine in a conserved subdomain that yields an inactive 
kinase but does not have any effect on the binding of the β and γ subunits within the 
complex (173).  To generate macrophage-specific CA-AMPKα1 and DN-AMPKα1 
transgenic mice for the purpose of this study, these constructs were sent to Dr. DeBroski 
Herbert, University of Cincinnati College of Medicine.  Dr. Herbert’s lab sub-cloned 
these constructs into a pNN265 vector that contains rabbit gamma globulin introns and 
poly A tail.  A 2 kb fragment was liberated by a Not1 digestion and inserted behind the 
1kb promoter sequence from human CD68 (macrosialin) including the 89 bp intronic 
enhancer (provided by Peter Murray at St. Jude Hospital) and confirmed by 
restriction digest and DNA sequencing. CD68-CA- or DN-AMPKα1 transgenic mice 
were generated by pronuclear injection of fertilized C57BL/6 oocytes at the University of 




Macrophage-specific DN-AMPKα1 mice develop spontaneous obesity associated 
with increased proinflammatory cytokine production  
Macrophage-specific CA-AMPKα1 and DN-AMPKα1 transgenic mice were 
successfully generated in Dr. Herbert’s lab and shipped to our lab.  A series of 
characterization studies were performed on these mice before the generation of 
macrophage-specific CA- or DN-AMPKα1 / LDLR-/- mice.  Genomic DNA was isolated 
from these mice from the tail tissue and was used for genotypic classification.  Based on 
the genotypic classification of these mice, BMDM were generated with the procedure 
described in the method.  Whole cell lysates were collected from the resting BMDM at 
day 7 of in vitro culture for Western blot analysis of basal level AMPK activity.   ACC is 
a substrate of AMPK and its phosphorylation level is generally used as indicator of 
AMPK regulation.  Both phospho-ACC and total-ACC expression level were detected by 
Western blot.  As shown in Fig. 5A, CA-AMPKα1 BMDM expressed elevated p-ACC 
compared to WT BMDM whereas DN-AMPKα1 BMDM expressed decreased p-ACC 
compared to WT BMDM, indicating constitutively activated AMPK activity in CA-
AMPKα1 mice and dominant negative AMPK expression in CA-AMPKα1 mice.  
Suprisingly, the F1 offspring of the macrophage-specific DN-AMPKα1 mice developed 
spontaneous whole body obesity after 16-20 weeks of age under the animal care facility 
in Baxter Research Center, University of Louisville (Fig. 5B).  The macrophage-specific 
CA-AMPKα1 mice and WT mice at the same age under the same animal care facility did 
not develop such phenotype.   Fatty liver was associated with the spontaneous obese 
phenotype of the macrophage-specific DN-AMPKα1 mice, and the expression of both A-






Figure 5. Macrophage-specific DN-AMPKα1 mice develop spontaneous obesity.  (A), 
Bone marrow derived macrophages (BMDM) were generated from macrophage-specific 
CA- or DN-AMPKα1 and wild type (WT) control mice.  Whole cell lysates were 
collected from the resting BMDM at day 7 of in vitro culture for Western blot analysis of 
both p-ACC and t-ACC detection.  The ACC phosphorylation level is analyzed by 
densitometry and shown as bar histogram.  (B), Photos were taken to show the weight 
difference between a WT and a DN-AMPKα1 mouse at 2 months of age.  Average body 
weight (n=4) was shown as bar histograms between the two groups.  Kupffer cells were 
isolated from the livers of these mice and whole cell lysate were generated for Western 











Table 1.  Macrophage-specific DN-AMPKα1 mice develop whole body obesity 
















liver of macrophage-specific DN-AMPKα1 mice (Fig. 5B).  We further harvested organs 
and fat tissues from different parts of the body from age-matched WT, macrophage-
specific CA-AMPKα1 or DN-AMPKα1 mice and compared their weights.  Differences in 
the weight of the organs and fat tissue between groups were shown in Table 1 (T. 1).  
Compared to WT and macrophage-specific CA-AMPKα1 mice, the weight of the liver 
and fat tissue isolated from macrophage-specific DN-AMPKα1 mice were higher (T. 1).   
Further characterization on these mice was performed by the evaluation of 
cytokine production in macrophages.  LPS-induced cytokine production in BMDM 
generated from these mice was measured by ELISA.  Expression of the proinflammatory 
cytokine, IL-6, was decreased in macrophages isolated from macrophage-specific CA-
AMPKα1 mice, whereas its expression was elevated in DN-AMPKα1 macrophages 
compared to in WT macrophages (Fig. 6).  The same expression pattern was also seen 
with TNFα and MCP-1.  These data suggest that the expression of dominant negative 
form of AMPKα1 in macrophages promotes a proinflammatory state in these transgenic 
mice.   
 
ABCA1 expression is increased in macrophages from macrophage-specific CA-
AMPKα1 mice  
The primary data we collected from the macrophage-specific CA- or DN-
AMPKα1 transgenic mice clearly suggested an import role of macrophage-expressed 
AMPK in the control of body weight growth and inflammatory cytokine productions.  
















Figure 6. Macrophage-specific DN-AMPKα1 mice are inflammation-prone compared to 
WT and CA-AMPKα1 mice.  Bone marrow derived macrophages (BMDM) generated 
from macrophage-specific CA- or DN-AMPKα1 and wild type (WT) control mice were 
incubated with LPS (10, 50, 100 ng) overnight.  Supernatants were collected for ELISA 
analysis of inflammatory cytokine production.  Data shown are mean ± SEM of triplicate 









spontaneous obese phenotype after the animals were transferred from the animal care 
facility in Baxter Research Center, University of Louisville to the animal care facility in 
Medical Dental Research (MDR) building, University of Louisville.  Additionally, in the 
process of crossbreeding between the macrophage-specific CA- or DN-AMPKα1 with 
LDLR-/-mice, the F1 offspring of these mice had lost the constitutively active or 
dominant negative expression of AMPKα1 activity in the macrophages isolated from 
bone marrow, peritoneal, and spleen.  We then put the macrophage-specific CA- or DN-
AMPKα1 and WT mice on a diet with 60% cal fat to test if the diet induced differential 
obesity development between the different genotypes of mice.  The body weights of these 
mice were measured every two days and were shown in Fig. 7A.  The organs and fat 
tissue were harvested from these mice and weighed between 70-80 days of HFD 
treatment (Table. 2).  Fat associated macrophages (FAM) were isolated from the fat 
tissue and were subjected to RT-PCR analysis of ABCA1 expression.   ABCA1 belongs 
to the family of ATP-binding cassette (ABC) transporters, and enhances cholesterol 
trafficking in macrophages and prevent atherosclerosis development (154, 174).  Deletion 
of ABCA1 in macrophages enhances atherosclerosis in mice (175).  Although the 
differences of the diet-induced obesity degree were not dramatically apparent as the 
spontaneous obese phenotype we observed in the macrophage-specific DN-AMPKα1 F1 
offspring (Fig. 5 and 7A), the macrophage-specific DN-AMPKα1 mice fed on HFD still 
possess higher fat tissue distribution all over the body compared to the macrophage-
specific CA-AMPKα1 and WT mice (Table. 2).  Interestingly, the FAM isolated from 
macrophage-specific CA-AMPKα1 fed on HFD expressed significantly elevated ABCA1 





 Figure 7. ABCA1 expression is increased in CA-AMPKα1 mice.  Macrophage-specific 
CA-AMPKα1 and DN-AMPKα1 transgenic mice with C56BL/6J control mice were 
placed on the diet for 80 days.  (A), Whole body weights of individual mice were 
assessed every two days.  Average body weight was shown as line histogram (n=10).  (B), 
Fat tissue was isolated from different parts of the body and weighed (weight shown in 
Table 2) before FAM isolation.  FAM were isolated from the fat tissue from these mice 
and were subjected to RT-PCR analysis of ABCA1 expression.  ABCA1 mRNA 
expression level was normalized to β-actin.  Data shown are mean ± SD of triplicate 











Table 2. Fat tissue weight chart of the macrophage-specific CA- or DN-AMPKα1 and 






















atheroprotective role of AMPK was observed in the subsequent mechanistic studies.   
 
AMPK enhances atheroprotective gene expression induced by IL-10 in macrophages 
While the unstable phenotype of the macrophage-specific CA- or DN-AMPKα1 
transgenic mice slowed down our research with the atherosclerosis disease model, in the 
meantime we found an interesting role of AMPK in regulating atherosclerosis-related 
signaling pathways in macrophages.   IL-10 is an important antiinflammatory/ 
atheroprotective cytokine regulating macrophage antiatherogenic functions in the way of 
promoting cholesterol trafficking via induction of PPARγ-mediated expression of 
atheroprotective genes such as ABCA1, apoE, and LXRα, thereby inhibiting 
proinflammatory gene expression (132).  Other  IL-10-induced genes include the 
antiinflammatory proteins such as SOCS family members which serve as effective 
counter-regulators to inflammatory TLR and cytokine stimuli, as well as Arg1, TGFβ and 
IL-10 itself (176).  IL-10 is also a potent activator of AMPK in macrophages (14).  To 
assess the role of AMPK in the regulation of macrophage functions in atherosclerosis, we 
examined expression of a panel of genes induced by IL-10 treatment at different time 
points post-stimulation (30 min - 18 h) in BMDM generated from AMPKα1+/+ and 
AMPKα1-/- mice.  As shown in Fig. 8, as expected, IL-10 stimulation increased mRNA 
expression of genes encoding apoE, SOCS1, SOCS3, LXRα, ABCA1, IL-10 and TGFβ 
in AMPKα1+/+ macrophages to varying degrees (1.2 to ~ 10-fold, peak expression time 
point is shown for each gene).  However, in AMPKα1-/- macrophages, IL-10 induction of 
expression of these genes was either abrogated (e.g., apoE, SOCS3, SOCS1, LXRα, 





Figure 8. AMPK enhances atheroprotective gene expression induced by IL-10 in 
macrophages.  BMDM generated from AMPKα1+/+ and AMPKα1-/- mice were treated 
with recombinant mouse (rm)-IL-10 (20 ng/ml) for the duration of 30 min, 1 h, 3 h, 6 h, 
and 18 h.  Total cellular lysates were collected for real-time PCR analysis.  The time point 
representing the peak level of expression for each gene is shown (representative result of 
two or more independent experiments).  Data shown are the mean ± SD of triplicate 







AMPKα1+/+ macrophages was modest (1.3 and 1.2 –fold respectively), however, 
interestingly, levels of expression in AMPKα1-/- macrophages were below the baseline 
levels of AMPKα1+/+.  We also noted that macrophage-derived MMP-9, which belongs 
to a family of protease-activated enzymes that can degrade various types of ECM 
proteins that has critical macrophage-mediated roles in atherosclerosis (177), was 
upregulated by IL-10 only in AMPKα1-/- macrophages, suggesting a counter-regulatory 
role of AMPK in MMP-9 expression.   
 
AMPK promotes apoE expression in macrophages  
ApoE is an important determinant of atherosclerosis and positive regulator of 
cholesterol efflux in macrophages.  Macrophages isolated from apoE-/- mice express 
markedly lower cholesterol efflux (178), and transplantation of bone marrow derived 
from apoE null mice resulted in a significant increase in atherosclerotic lesion size 
compared to controls in C57BL/6 mice (179).  Conversely, transplantation of bone 
marrow from wild-type mice into apoE-null mice slowed the progression of 
atherosclerosis (180, 181).  These researches suggest that myeloid expression of apoE is 
critical to attenuate atherosclerosis initiation and progression.  Interestingly, as is the case 
for AMPK (14), apoE has also been recognized as a regulator of macrophage functional 
plasticity that promotes an antiinflammatory phenotype (182, 183).  IL-10 and PPARγ are 
suggested responsible for apoE expression in macrophages (133, 135).  IL-10 induced 
significant increase of apoE expression in macrophages, and this effect was abrogated in 
macrophages deficient in AMPK expression (Fig. 8), suggesting that IL-10-induced apoE 


















Figure 9. AMPK promotes ApoE expression in macrophages.  (A), stable transfected 
macrophage cell line that express CA-AMPKα1 and the control empty vector were 
generated and treated with recombinant mouse (rm)-IL-10 (20 ng/ml) for 1h.  Whole cell 
lysates were collected for real-time analysis of ApoE expression.  (B), BMDM generated 
from AMPKα1+/+ and AMPKα1-/- mice were treated with rosiglitazone (2μM) for 1h.  
Whole cell lysates were collected for real-time analysis of ApoE expression.  (C), 
BMDM generated from C56BL/6J mice were transfected with AMPK siRNA and control 
non-targeting siRNA.  24h post transfection, 20ng/ml rm-IL-10 or 2μM rosiglitazone 




time PCR for ApoE expression.  ApoE mRNA expression levels were normalized to β-
actin.  Data shown are mean ± SD of triplicate determinations.  All the data are from one 
























This AMPK dependency was further investigated in macrophage cell line that 
expresses CA-AMPKα1 stimulated with IL-10 and with the use of a PPARγ agonist, 
rosiglitazone.  As shown in Fig. 9A, CA-AMPKα1 macrophages express remarkably 
elevated apoE (~60-fold) at both basal levels and with IL-10 stimulation compared to the 
control cell line.  Similar to IL-10 stimulation, treatment with rosiglitazone resulted in 
increased apoE mRNA transcription about 2-fold 1h post stimulation, and this effect was 
abrogated in AMPKα1-/- macrophages (Fig. 9B).  Likewise, silencing of AMPK 
expression with siRNA transfection led to inability for both IL-10 and rosiglitazone to 
induce apoE expression.  These data support a critical role of AMPK in mediating apoE 
expression in macrophages, and this AMPK-dependency may contribute greatly in the 
regulation of macrophage function in inflammatory responses as well as cholesterol 
trafficking that both play important roles in atherosclerosis.   
 
Relationship between PPARγ and AMPK in macrophages  
In our hypothesis, a mechanistic link between FABP/PPARγ/IL-10/AMPK is 
suggested as the underlying mechanism of AMPK regulation of macrophage 
atherosclerosis-related functions.  To test this hypothesis, a variety of PPARγ agonists 
including 13-HODE, 15dPGJ2, rosiglitazone and antagonist such as GW9662 was used 
to activate or block PPARγ activity and the effect on AMPK expression and activation 
was evaluated.  PPARγ expression was sufficiently silenced by 24h siRNA transfection in 
Fig. 10A, whereas AMPK expression was not affected by this treatment, indicating that 
PPARγ expression itself does not affect AMPK expression.  However, inhibition of 





Figure 10. PPARγ activity positively regulates AMPK.  (A), BMDM generated from 
C56BL/6J mice were transfected with PPARγ siRNA or control non-targeting siRNA.  
Whole cell lysates were collected 24h post transfection for real-time analysis of PPARγ 
and AMPKα1 expression.  (B), BMDM generated from C56BL/6J mice were treated with 
LPS (100ng/ml) alone, or LPS (100ng/ml) with GW9662 (2μM) for 24 h.  Cell lysates 
were analyzed by real-time PCR for AMPKα1 expression.  (C), BMDM generated from 
C56BL/6J mice were treated with LPS (100ng/ml) alone, or LPS (100ng/ml) with 
GW9662 (2μM) for 12 h.  Cell lysates were analyzed by Western blot for AMPKα-




Figure 10, continued.  (D), BMDM generated from C56BL/6J  mice were treated with 
15dPGJ2 (3μM). Whole cell lysates were collected at 0, 10’, 30’, 1h, 6h post stimulation 
respectively for Western blot assessment of AMPKα-Thr172 phosphorylation.  (A and B), 
gene mRNA expression levels were normalized to β-actin.  Data shown are mean ± SD of 
triplicate determinations.  (C and D), AMPK activation level was analyzed by 
densitometry and displayed as bar histogram.  The results shown are representative of 




















the expression of AMPKα1 mRNA and this reduction of expression was about 80-fold 
higher than LPS alone group (Fig. 10B), indicating that inhibition of PPARγ activity led 
to reduced AMPK expression in macrophages.  This finding is supported by Western blot 
analysis of AMPK activity in macrophages treated with GW9662 and/or LPS.  12h 
treatment of LPS resulted a reduction of AMPK activation (Fig. 10C), this result is 
consistent with the data we showed prevously (14).  Compared to the LPS treated group, 
treatment with GW9662 resulted more potent inhibition on AMPK activation and the 
cobination of LPS and GW9662 completely abrogated AMPK activation (Fig. 10C).  
Conversely,  1-6 h treatment of PPARγ agonist 15dPGJ2 resulted AMPK activation in 
macrophages (Fig. 10D).  These data supported our hypothesis that elevated PPARγ 
activity results in increased AMPK activity in macrophages.   
We noticed that the PPARγ agonist 15dPGJ2 activates AMPK at a relatively late 
time point (6h).  This late activation implicates an indirect regulation of AMPK activity 
mediated by PPARγ inducible gene expression.  Because PPARγ promotes IL-10 
expression and IL-10 activates AMPK (14, 158), IL-10 is likely the intermediate factor 
that links PPARγ and AMPK activity.  To verify the role of IL-10 in this PPARγ/AMPK 
regulation, we used a neutralization antibody to block endogenous IL-10 signaling.  
Before use, the efficacy of this antibody was demonstrated by examination of IL-10-
induced signal transducer and activator of transcription 3 (STAT3) activation with anti-
IL-10 pretreatment.  IL-10 induces rapid STAT3 activation in macrophages (184).  1h 
pretreatment with anti-IL-10 antibody at concentration of 50-150 ng/ml efficiently 
blocked IL-10 activation of STAT3 (Fig. 11A).  Like 15dPGJ2, stimulation with PPARγ 






Figure 11. PPARγ agonists induce AMPK activation and require IL-10 expression.  (A), 
BMDM generated from C56BL/6J mice were treated with anti-IL-10 neutralization 
antibody (50, 100, 150 ng/ml) 1h pre-incubation, then exposed to rm-IL-10 (20ng/ml) 
stimulation for 1h.  Cell lysates were analyzed by Western blot for STAT3-Tyr705 
phosphorylation.  (B), BMDM generated from C56BL/6J mice were treated with anti-IL-
10 neutralization antibody (100 ng/ml) 1h pre-incubation, then exposed to 13-HODE 
(10μM) for indicated time.  Cell lysates were analyzed by Western blot for AMPK-
Thr172 phosphorylation.  (C), BMDM generated from C56BL/6J mice were treated with 
anti-IL-10 neutralization antibody (100 ng/ml) 1h pre-incubation, then exposed to 




Figure 11, continued.  Cell lysates were analyzed by Western blot for AMPK-Thr172 and 
ACC-Ser79 phosphorylation.  (D), BMDM generated from C56BL/6J mice were treated 
with GW9662 (2μM) for1h pre-incubation, then exposed to rosiglitazone (2μM) for the 
indicated times.  Cell lysates were analyzed by Western blot for AMPK-Thr172 
phosphorylation.  Protein activation levels were analyzed by densitometry and displayed 





















anti-IL-10 neutralization antibody abolished this effect (Fig. 11B).  A similar effect was 
also seen upon stimulation with another PPARγ agonist, rosiglitazone, without or with 
IL-10 neutralization (Fig. 11C).  Interestingly unlike 15dPGJ2 induced AMPK activation, 
an early activation of AMPK between 10 min to 1 h was observed with stimulation by 
13-HODE or rosiglitazone (Fig. 11B and C).  To test if this early activation of AMPK by 
PPARγ agonists was mediated by PPARγ activity, we pretreated BMDM with GW9662 
to block PPARγ activity followed by stimulation with rosiglitazone.  The early AMPK 
activation stimulated by rosiglitazone was not affected by GW9662 pretreatment (Fig. 
11D), suggesting this early AMPK activation by PPARγ agonist is independent of 
PPARγ activity.  These data demonstrated that PPARγ activity positively regulates 
AMPK activity in macrophages, and this regulation requires IL-10 signaling. 
An interesting result was observed during the research of PPARγ/AMPK 
relationship.  We noticed that silencing of AMPK expression by siRNA also suppressed 
PPARγ expression (Fig. 12A), in contrast to the observation that PPARγ siRNA 
treatment did not affect AMPK expression (Fig. 10A), and suggested a positive 
regulation of PPARγ expression by AMPK.  This conclusion is supported by the data we 
collected from the CA-AMPKα1 macrophage cell line, which showed an elevated PPARγ 
expression at both baseline and IL-10 stimulated level (Fig. 12B).   
Our data showing that PPARγ activity positively regulates AMPK activation via 
IL-10 production, and AMPK in turn, regulates PPARγ expression, indicated that there is 















Figure 12. AMPK positively regulates PPARγ expression.  (A), BMDM generated from 
C56BL/6J mice were transfected with AMPK siRNA and control non-targeting siRNA.  
Whole cell lysates were collected 24h post transfection for real-time analysis of PPARγ 
and AMPKα1 expression.  (B), CA-AMPKα1 and the control macrophage cell line were 
treated with rm-IL-10 (20ng/ml) for 1 h.  Whole cell lysates were collected for real-time 
analysis of PPARγ expression.  Data shown are mean ± SD of triplicate determinations. 
All the data are one representative experiment out of two independent experiments with 











Macrophages are key players in atherosclerosis.  They perform a variety of 
regulatory functions including lipid trafficking, energy homeostasis, and inflammatory 
responses that are closely related to every step of atherogenesis from lesion formation to 
plaque destabilization.  The physiological microenvironment within atherosclerosis lesion 
contains diverse factors with opposing influences of inflammation properties, such as 
IFNγ or IL-10, that have the potential to promote macrophage functional adapt towards 
either atherogenic or antiatherogenic directions, respectively.  Our research has 
established a key regulatory role of AMPK in macrophage inflammatory functions (14).  
Antiinflammatory stimulation with IL-10 activates AMPK, thus turns on the signaling 
events that eventually lead to suppression of NF-κB mediated proinflammatory cytokine 
productions while enhancing IL-10 production.  
The primary data we collected from the macrophage-specific CA-AMPKα1 and  
DN-AMPKα1 transgenic mice provided valuable evidence to support a counter 
regulatory role of macrophage expressed AMPK in the development of metabolic 
syndromes including obesity and atherosclerosis.  Transgenic mice that expressed a 
dominant negative form of AMPK specifically in their macrophages had more inflamed 
macrophages and were more susceptible to obesity, even without intake of excessive 
dietary fat (Fig. 5 and 6).   On a HFD, these mice developed excessive fat all over the 




AMPKα1 showed much higher levels of ABCA1, indicating accelerated cholesterol 
trafficking in their fat associated macrophages (Fig. 7).  Although the instability of the 
phenotypes of these transgenic mice caused an unexpected gap for this research, a 
mechanism demonstrating a co-dependent relationship between PPARγ and AMPK in 
macrophages provided futher evidence to support the beneficial role of AMPK in 
atherosclerosis (Fig. 10-12).   
 
More importantly, a requirement of AMPK for the potent antiinflammatory/ 
antiatherogenic cytokine IL-10 to induce atheroprotective gene expression including 
ABCA1, apoE, LXRα, and IL-10 itself, was discovered.  This discovery is important due 
to the broad-reaching significance of IL-10 in maintaining immune homeostasis, and in 
the regulation in many inflammatory diseases including obesity, atherosclerosis, 
autoimmune disease, and cancer.  The investigation of the role of AMPK in IL-10 
mediated signaling events that eventually led to genetic modification of macrophage 
functions may provide valuable insights into therapies of a broad range of inflammatory 
diseases including atherosclerosis as well as the understanding of IL-10’s suppressive 
functions to maintain immune homeostasis in the body.  Experiments were then carefully 








    AMPK REGULATES IL-10-MEDIATED ANTIINFLAMMATORY SIGNALING 




In the process of investigating of the regulatory mechanisms of AMPK in 
macrophage functional polarization in atherosclerosis, we found that AMPK is essential 
for IL-10-induced expression of genes including these encoding apoE and suppressor of 
cytokine signaling 3 (SOCS3) (Fig. 8).  In addition to AMPK (14), ApoE is also 
recognized as a regulator of macrophage plasticity that promotes antiinflammatory 
phenotype (182, 183).   SOCS3 is an established inhibitory protein rapidly induced by IL-
10, and potently inhibits inflammatory responses in many cell types including 
macrophages (185, 186).  Our discovery of a requirement of AMPK for IL-10-mediated 
gene expression led us to re-focus efforts on the role of AMPK in IL-10 signal 
transduction.  In doing so, an essential role of AMPK in IL-10-mediated 
antiinflammatory signaling and function was evident by data demonstrating a 
requirement of AMPK in IL-10 activation of the PI3K/Akt/mTOR and STAT3/SOCS3 




well studied in non-immune cells such as endothelial cells and SMCs.  Recent studies 
revealed the importance of leukocyte AMPK in the immune suppression of inflammation 
in health and disease (187).  This study of AMPK regulation of IL-10-mediated 
antiinflammatory signaling pathways and functions in macrophages is an important 
addition to the understanding of AMPK biological functions and the underlie 
mechanisms of the suppressive immune surveillance, therefore provides the fundamental 




The role of AMPK in mediating metabolic pathways in the body is well studied.  
Recent work has also established an association of AMPK activity with inflammatory 
potential in leukocytes (11, 13-15, 111).   For example, silencing of AMPKα1 in 
macrophages or forced expression of a dominant negative form of AMPKα1 results in 
amplification of inflammatory activity, whereas treatment with agents that activate 
AMPK is suppressive (14).  Stimulation of macrophages with proinflammatory agents 
such as LPS reduces AMPK phosphorylation, whereas stimulation with antiinflammatory 
agents  (e.g., IL-10, IL-4 and TGFβ) results in elevated levels of phospho-AMPK (14).  
Likewise, TLR activation by LPS in DCs induced decreased AMPK activation and this 
effect was accompanied by increased cellular glucose consumption (110).  We 
demonstrated recently that AMPK deficiency in DC results in a heightened inflammatory 
response to CD40 stimulation, resulting in an increased capacity to induce Th1 and Th17 




responsible for T cell immunoglobulin- and mucin domain-containing molecule-4 (TIM-
4)-mediated autophagic degradation of apoptotic tumor cells in macrophages and the 
subsequent immunosuppressive phenotype macrophages acquire during this process (13).  
In addition to the discovery of upstream regulators including LKB1, CaMKKβ, and Tak1 
kinase (42), identified mechanisms of AMPK-induced suppression of inflammatory 
signaling in macrophages include activation of inhibitory PI3K-mediated pathways (14) 
and enhancement of SIRT1 activity and expression leading to NF-κB deacetylation (109).   
Studies focusing on AMPK regulation of metabolic pathways in leukocytes have 
contributed to the emergent paradigm that increased glycolysis is associated with 
inflammatory activity and proliferation, whereas reduced glycolysis and enhanced 
oxidative metabolism is associated with suppressed inflammation and quiescence (11).  
However, activators of AMPK not only suppress inflammatory responses but re-polarize 
leukocytes by actively inducing programs of antiinflammatory gene expression.  The 
observation that antiinflammatory cytokines, including IL-10, induce rapid activation of 
AMPK in macrophages (14) suggests that AMPK serves as an immediate upstream 
signaling molecule in antiinflammatory pathways.   
 
IL-10 signaling  
IL-10 is a potent immunosuppressive cytokine that systemically limits excessive 
inflammation and controls inflammatory disease progression (160, 161).  The 
antiinflammatory function of IL-10 has been well studied in murine models of 
inflammatory disease including inflammatory bowel disease (IBD), experimental allergic 




pathways activated through IL-10 receptor ligation have received less attention.  Two 
important signaling cascades have been reported to mediate IL-10 suppressive functions 
in macrophages, the PI3K/Akt and JAK/ STAT3 pathways (184, 190). 
 
IL-10 activates PI3K/Akt pathway  
IL-10 is reported to promote PI3K/Akt activation.  Pharmaceutical inhibition of 
PI3K in macrophages impairs IL-10-induced gene expression, as well as IL-10-mediated 
suppression of LPS-induced proinflammatory gene expression and this effect is reversed 
by the expression of a constitutively active Akt (190).  Although PI3K and Akt activity 
can be induced by IL-10 stimulation in pro-myeloid cells (191), the direct activation of 
PI3K by IL-10 in macrophages has not yet been reported.  Class IA PI3Ks are composed 
of a catalytic subunit (p110α, p110β, or p110δ) and a tightly associated regulatory subunit 
(p85α, p85β, p55γ, p55α, or p50α).  The regulatory p55 subunit results from the alternate 
transcription of the pik3r1 gene (192-194).  It associates with the catalytic subunit p110 
and coordinates unique PI3K kinase functions such as the induction of cell cycle arrest 
(195, 196) and prevention of xenograft tumor growth (197).  Physiological stimulation 
such as IL-10 induces phosphorylation of the regulatory subunit of PI3K and results in 
PI3K activation.  Once activated, PI3K converts PtdIns(3,4)P2 (PIP2) into PtIns(3,4,5)P3 
(PIP3), and promotes the accumulation of PIP3 on plasma membrane, which leads to 
colocalization of phosphoinositide-dependent protein kinase 1 (PDK1) and Akt to the 
plasma membrane where PDK1 phosphorylates Akt directly on Thr308 (198-200).  In 
contrast, phosphatase and tensin homologue deleted on chromosome ten (PTEN) reverses 




Phosphorylation on three phosphorylation sites, serine-380, threonine-382 and -383 
(Ser380/Thr382/383) maintains PTEN at a more stable state of expression (202).  PDK1 
is constitutively active in cells with different sites phosphorylated in the absence of 
stimulation, yet so far only serine-241 (Ser241) is proved to be essential for PDK 
function (199, 203).  Phosphorylation of both Thr308 in the activation loop and Ser473 in 
the kinase tail enhances the activation of Akt (198).   
 
Activation of Akt promotes mTORC1 and GSK3β/CREB activation 
Activation of Akt mediates many downstream biological events including the 
direct activation of mammalian target of rapamycin (mTORC1) (204).   Relevant to the 
work presented herein, it has been reported that IL-10 stimulation of primary monocytes 
results in elevated mTORC1 activity and this effect is abrogated by PI3K inhibition 
(205).  IL-10 prevents LPS-induced proinflammatory gene expression by the inhibition of 
NF-κB activation (206) via the PI3K/Akt/GSK3β pathway (190).  Phosphorylation/ 
inactivation of glycogen synthase kinase-3 β (GSK3β) promotes the competitive binding 
of the nuclear coactivator CBP to cAMP response element-binding protein (CREB), 
therefore negatively regulates NF-κB activity (207).  Interestingly, an inhibitory role of 
AMPK was observed in IκB degradation and NF-κB activation, and CA-AMPKα1 
macrophages express increased CREB activation in response to LPS stimulation (14).   
 
IL-10 activates JAK/STAT3/SOCS3 pathway  
Although the precise mechanism of activation of PI3K/Akt signaling via IL-10 in 




tyrosine kinases (JAKs) and the subsequent phosphorylation/activation of STAT3 and 
STAT3-directed expression of SOCS3 is well-established (184, 208-211).  In addition to 
the tyrosine phosphorylation events in this pathway, phosphorylation on serine residues 
within the IL-10 receptor intracellular domain and within STAT3 homodimer complexes 
are also important for IL-10/STAT3 suppressive function (212-214).  Interestingly, 
mTORC1 was reported to mediate STAT3 serine phosphorylation in different cell types 
and data suggests that this serine phosphorylation is required for optimal activation of 
STAT3 (215-218).  Following STAT3 activation, the rapid expression of SOCS3 protein 
potently suppresses TLR inflammation in different cell types including macrophages 
(185, 219, 220).  The mTORC1 protein complex is shown to negatively regulate innate 
inflammatory responses in myeloid immune cells (221, 222) and, in contrast to non-
immune cells in which AMPK typically inhibits mTORC1 (223), evidence suggests that 
AMPK activity positively regulates mTORC1 activity in macrophages (224).    
 
Given the rapid and robust activation of AMPK in response to IL-10 stimulation, 
herein we addressed the hypothesis that AMPK orchestrates PI3K/Akt/mTORC1, 
PI3K/Akt/CREB and JAK/STAT3/SOCS3 signaling pathways to contribute to IL-10-





MATERIAL AND METHODS 
 
Reagents 
Recombinant mouse IL-10 was purchased from R&D Systems.  LY294002, JAK 
inhibitor I, and rapamycin were purchased from Calbiochem (EMD Millipore) and STO-
609 was purchased from Tocris Biosciences.  The Jak inhibitors AG490 and CP-690, 550 
were purchased from LC Laboratories Ltd.  Western blot detection of specific proteins 
used the following primary Abs: anti-phospho-AMPKα (Thr172), anti-AMPKα, anti-
phospho-PI3 kinase p85 (Tyr458)/p55 (Tyr199), anti-PI3 kinase p55, anti-PI3 kinase p85, 
anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), anti-Akt, anti-phospho-GSK3β 
(Ser9), anti-GSK3β, anti-phospho-CREB (Ser133), anti-CREB, anti-phospho-mTOR 
(Ser2448), anti-mTOR, anti-phospho-p70 S6K (Ser371), anti-p70 S6K, anti-phospho-
TSC2 (Ser939), anti-phospho-TSC2 (Ser1387), anti-TSC2, anti-phospho-Stat3 (Tyr705), 
anti-phospho-Stat3 (Ser727), anti-Stat3, anti-phospho-JAK1 (Tyr1022/1023), anti-JAK1, 
anti-SOCS3 (Cell Signaling Technology), anti-β-actin (Sigma-Aldrich), and HRP-
conjugated secondary Ab (Jackson ImmunoResearch Laboratories).  
 
Mice and Cell culture 
AMPKα1 deficient (AMPKα1-/-) mice were generated as previously described (170).  




AMPKα1-/- mice and their littermate controls, AMPKα1+/+ mice, were bred and 
maintained in the Research Resources Facility, University of Louisville. All animal care 
and experimental procedures were approved by the Institutional Animal Care and Use 
Committee, University of Louisville.  Bone marrow-derived macrophages (BMDM) were 
generated from C57BL/6J mice, AMPKα1+/+ and AMPKα1-/- mice following the 
protocol previously described (171).  BMDM were maintained in incubators set to 37°C 
and 5% CO2.  For stimuli/reagents used in individual experiments, BMDM were 
harvested into a 24-well cell culture plate and rested overnight in RPMI medium 
supplemented with 5% FBS, 10 mM HEPES Buffer (Sigma), and 10 μg/ml gentamycin 
(Atlanta Biologicals) (referred as R5 medium) prior to stimulus.  The cells were quickly 
rinsed with pre-warmed DPBS supplemented with 2% FBS before lyse.  
 
Western blot analysis 
Whole cell lysates were generated by lysis with a buffer containing 125 mM Tris (pH 
6.8), 2% SDS, 20% glycerol, 100 μM PMSF, protease inhibitor mixture (Promega), and 
HALTTM phosphatase inhibitor cocktail (Thermo Scientific).  Total protein content of the 
samples was assessed by BCA protein assay (Pierce).  Equal amounts of protein were 
separated on 10% Criterion gels (Bio-Rad) by SDS-PAGE.  Medium and high molecular 
weight proteins (55-289KDa) were transferred to nitrocellulose membranes using a 
Trans-Blot® TurboTM Nitrocellulose Transfer Pack and Trans-Blot®TurboTM transfer 
system (Bio-Rad).  Low molecular weight proteins (< 55kDa) were transferred to 
nitrocellulose membranes (Hybond; Amersham Biosciences) using a Trans-Blot SD 




an ECL Western blotting analysis system (Amersham Corp.), and the membranes were 
exposed to SRX-101A film (Konica Minolta).  Densitometry analysis was performed 
using the UN-SCAN-IT gel (version 6.1) software.  
 
Real-time RT-PCR analysis 
mMACsTM One-step cDNA Kit (Miltenyi Biotech) were used for RNA isolation and 
cDNA synthesis. cDNAs were amplified in a 20 μl reaction volume containing SYBR 
Green (New England Biolabs) and analyzed using a DNA Opticon 2 Monitor (MJ 
Research).  All the gene mRNA expression levels (tnfa, il-6, and il-12b) were analyzed by 
Quantitect Primer Assays (Qiagen).  The cDNA concentrations in each sample were 
normalized using transcripts for β-actin.  The relative expression software tool (REST©) 
was used to quantify mRNA expression (172).   
 
ELISA 
Following stimulation in 24-well plates, supernatants were collected into 96-well plates 
and assayed by ELISA using OptEIATM sets (BD Biosciences Pharmingen) according to 
the manufacturer’s instructions.  Analysis was performed using an E-max precision micro 
plate reader (Molecular Devices). 
 
Statistical Analysis  
Statistical significance between groups was calculated with an unpaired Student’s t test, 






IL-10 activates AMPK on a time dependent manner 
Our previous research demonstrated a time-dependent activation of AMPK by 
antiinflammatory factors, including IL-10, in macrophages generated from wild-type 
mice (14).  The influence of IL-10 stimulation on AMPK activation was tested with 
macrophages generated from both AMPKα1+/+ and AMPKα1-/- mice (Fig. 13).  IL-10 
stimulation induced rapid AMPK activation in AMPKα1+/+ macrophages within 5 min, 
as confirmed by both phosphorylation on AMPKα and ACC (Fig. 13A), and this 
activation persisted as long as the IL-10 stimulation up to > 8 h (Fig. 13B).  Both 
phosphorylated- and total- AMPK expression were wiped out in AMPKα1-/- mice (Fig. 
13 A and B).  This result revealed a potent role of IL-10 in AMPK activation in 
macrophages and confirmed the deficient expression of AMPK in AMPKα1-/- mice, 
which provides a good tool for the studies to investigate the role of AMPK in IL-10 
signaling transduction.    
 
AMPK is required for IL-10 activation of PI3K/Akt pathway 
The data shown in Figure 8 demonstrate a role of AMPK in IL-10-mediated gene 
expression, including expression of SOCS3 which has been shown to be largely 
responsible for the ability of IL-10 to suppress TLR-mediated inflammatory responses 












Figure 13. IL-10 activates AMPK in a time-dependent manner.  BMDM generated from 
AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 ng/ml) for the time 
points indicated.  Cell lysates were analyzed by Western blot for (A), AMPKα-Thr172 
and ACC-Ser79 phosphorylation and (B), AMPKα-Thr172 phosphorylation.  The results 

















IL-10 function.  IL-10 is reported to activate the PI3K/Akt pathway in macrophages (190, 
191), however direct phosphorylation of PI3K in macrophages through IL-10 stimulation 
has not been shown.  With BMDM generated from AMPKα1+/+ mice, we demonstrated 
that IL-10 stimulation induced rapid AMPK activation, as indicated by elevated 
phosphorylation of AMPKα-Thr172 residue and phosphorylation of ACC-Ser79 residue 
within 5 minutes (Fig. 13A).  This effect was accompanied by more than 2 fold increase 
of the phosphorylation level of the PI3K p55 regulatory subunit within 15 minutes (Fig. 
14A).  IL-10 induced PI3K activation was not apparent in AMPKα1-/- BMDM (Fig. 
14A).  Interestingly, we noted that the overall expression level of the PI3K p55 subunit 
was ~1.5 fold lower in AMPKα1-/- BMDM compared to AMPKα1+/+ BMDM, while the 
level of p85 subunit expression was similar in both groups.  Moreover, elevated PI3K p55 
phosphorylation level was observed in CA-AMPKα1 macrophage cell line at both 
baseline and IL-10 stimulated levels compared to the control macrophages (Fig. 14B).  
We failed to detect phosphorylated PI3K p85 in both AMPKα1+/+ and AMPKα1-/- 
BMDM and the transfected macrophage cell lines in repeated experiments, indicating a 
novel role of IL-10-induced AMPK in the activation of the PI3K p55 regulatory subunit, 
specifically.   
 The data in Figure 14 suggested that IL-10 induces transient PI3K activation.  The 
expression of AMPK is required for this effect, and constitutively active AMPK enhances 
this effect.  To test if AMPK is upstream of PI3K activation in IL-10 signal transduction, 
we pretreated macrophages generated from C57BL/6J mice with the PI3K inhibitor 
LY294002, then stimulated the cells with IL-10.  Cell lysates were collected at both early 















Figure 14. AMPK positively regulates IL-10-induced PI3K activation.  (A), BMDM 
generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 
ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for p-
PI3K p55 (Tyr199), t-PI3K p55, and t-PI3K p85 expression.  (B), CA-AMPKα1 and the 
control macrophage cell line were treated with rm-IL-10 (20ng/ml) for indicated time.  
Cell lysates were analyzed by Western blot for PI3K p55-Tyr199 phosphorylation.  PI3K 
activation/ phosphorylation levels were analyzed by densitometry and displayed as bar 



















Figure 15. PI3K inhibitor LY294002 does not block IL-10-induced AMPK activation. 
BMDM generated from C56BL/6J mice were treated with LY294002 (20mM) for 1h pre-
incubation, then exposed to rm-IL-10 (20ng/ml) stimulation for indicated time.  Cell 
lysates were analyzed by Western blot for (A), Akt-Ser473 and Akt-Thr308 
phosphorylation (upper panel), AMPK-Thr172 phosphorylation (lower panel), and (B), 
Akt-Ser473 phosphorylation (upper panel), AMPK-Thr172 phosphorylation (lower 




















Figure 15, continued.  Activation level of proteins were analyzed by densitometry and 














levels.  Akt is a downstream target for PI3K phosphorylation and its phosphorylation/ 
activation was used as an indicator of PI3K inhibition by LY294002.  As showed in Fig. 
15A, upper panels, pretreatment with LY294002 completely blocked IL-10-induced Akt 
phosphorylation of both serine and threonine residues, and this was evident throughout a 
5’-18h time period  (Fig. 15B, upper panels).  LY294002 pretreatment resulted in a slight 
impairment of early phosphorylation of AMPK induced by IL-10 stimulation but 
phosphorylation returned to control levels after 30 min, and was higher in the LY294002 
pretreated macrophages at the later time points (Fig. 15, lower panels). LY294002 is 
capable of suppressing calcium entry into the cells independent of its inhibition on PI3K 
activity (226, 227) thus the early inhibition of AMPK by LY294002 may due to 
LY294002 inhibition of Ca2+ influx leading to the inhibition of the AMPK upstream 
regulator CaM-KKβ (54).  These results demonstrate that IL-10 activation of AMPKα1 is 
upstream of PI3K/Akt signaling in macrophages.   
 
 Akt activation is a mutiple-step process that is mediated by several up-stream 
signaling proteins including PI3K, PTEN, and PDKs.  PTEN is a phosphatase that 
counters PI3K phosphorylation of PIP2, therefore negatively regulates Akt activation. 
CA- or DN- AMPKα1 macrophages cell lines stimulated with IL-10 indicated a negative 
role of AMPK in PTEN phosphorylation/expression, as demonstrated in Figure 16: the 
phosphorylated/activated AMPKα1 is constitutively expressed in CA- AMPKα1 
macrophages, whereas in these macrophages the expression of both phosphorylated and 
total level of PTEN is decreased (Fig. 16A).  However PTEN phosphorylation and 










Figure 16. AMPK negatively regulates PTEN activity in response to IL-10.  (A), CA-
AMPKα1, DN-AMPKα1, and the control macrophage cell line were treated with rm-IL-
10 (20ng/ml) for indicated time.  Cell lysates were analyzed by Western blot for AMPKα-
Thr172 and PTEN-Ser380/Thr382/383 phosphorylation.  (B), BMDM generated from 
AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 ng/ml) for the time 
points indicated.  Cell lysates were analyzed by Western blot for PTEN-
Ser380/Thr382/383 phosphorylation.  The results shown are representative of two or 













isolated from AMPKα1-/- bone marrow (Fig. 16 A and B).  These results suggest that in 
macrophages, AMPK activity is not necessary for PTEN phosphorylation or expression, 
but increased AMPK activity enhances the suppression of PTEN activity, thereby 
favoring the conversion from PIP2 to PIP3 and thus promoting the co-localization of 
PDK1 and Akt.   
 
 The data in Figure 15 showed that IL-10 stimulation induced Akt activation in 
AMPKα1+/+ macrophages, suggesting that Akt is a part of IL-10-mediated signaling 
pathways.  The fact that inhibition of PI3K activity abrogated Akt activation indicated 
that IL-10 induced Akt activation depends on PI3K activity (Fig. 15).  These results also 
suggest that PDK1 may also be a part of the IL-10-induced activation of PI3K/Akt 
pathway.  To test if PDK1 is also regulated by AMPK activity, we generated macrophages 
from AMPKα1+/+ and AMPKα1-/- mice and stimulated the cells with IL-10.  Although 
the phosphorylation of PDK1-Ser241 site is constitutively active, stimulation with IL-10 
still induced a slight increase of p-PDK1-Ser241 in AMPKα1+/+ macrophages where as 
this effect was not observed in AMPKα1-/- macrophages (Fig. 17).  Interestingly, like the 
total-PI3K p55 level (Fig. 14A), the overall total-PDK1 expression level was also 
reduced in AMPKα1-/- macrophages (Fig. 17).  This result suggested that AMPK 
expression in macrophages has a positive effect in the maintenance of PDK1 activity and 
expression.   
 
 The data in Figures 14-17 have suggested a positive role of AMPK in the 










Figure 17. AMPK positively regulates PDK1 activity in response to IL-10.  BMDM 
generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 
ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for 
PDK1-Ser241 phosphorylation.  PDK1 activation level was analyzed by densitometry 





















Figure 18. AMPK is required for IL-10-induced Akt activation.  BMDM generated from 
AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 ng/ml) for the time 
points indicated.  Cell lysates were analyzed by Western blot for p-Akt (Thr308) (upper 
panel) and p-Akt (Ser473) (lower panel) expression.  The results shown are 

















macrophages.  We then tested the influence of AMPK in Akt activation in IL-10 signal 
transduction.  The level of Akt phosphorylation in AMPKα1-/- macrophages was greatly 
reduced as compared with levels present in AMPKα1+/+ macrophages.  Phosphorylation 
of Thr308 was reduced ~3.5 fold (Fig. 18, upper panel) and phosphorylation of Ser473 
was reduced ~8.5 fold (Fig. 18, lower panel) indicating a significant impairment of IL-
10’s ability to activate Akt in the absence of AMPKα1 expression.   
 
Overall, results from Figure 14-18 demonstrate that IL-10 activation of AMPKα1 
is upstream of PI3K/Akt signaling in macrophages.   
 
AMPK positively regulates IL-10 activation of Akt/CREB pathway  
Activated Akt regulates numerous cellular functions including cytokine 
expression, apoptosis, and proliferation (228, 229).  The IL-10 PI3K/Akt/GSK3β 
pathway is known to mediate the IL-10 suppression of LPS-induced NF-κB inflammation 
(190, 206).  We previously reported evidence that supports a positive role of AMPK in 
the regulation of the LPS-induced GSK3β/CREB pathway in macrophages (14).  Based 
on these studies and the data supporting positive AMPK regulation of PI3K/Akt pathway, 
the role of AMPK in the regulation of IL-10-mediated GSK3β/CREB pathway was 
tested.  The level of GSK3β phosphorylation remains intact in IL-10 stimulated 
macrophages in repeated experiments (Fig. 19A).  Interestingly IL-10 stimulation 
induced robust CREB-Ser133 phosphorylation despite the unresponsiveness of GSK3β 
phosphorylation to IL-10.  IL-10 induced CREB activation was abrogated in DN-













Figure 19. AMPK positively regulates IL-10 activation of GSK3β/CREB pathway.  (A), 
BMDM generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 
(20 ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for 
p-GSK3β (Ser9) and t-GSK3β expression.  (B), CA-AMPKα1, DN-AMPKα1, and the 
control pcDNA-Zeo macrophage cell line were treated with rm-IL-10 (20ng/ml) for the 
indicated times.  Cell lysates were analyzed by Western blot for CREB-Ser133 
phosphorylation.  CREB activation level was analyzed by densitometry and displayed as 










This pattern demonstrates that in response to IL-10 stimulation, activated AMPK 
promotes Akt activation that leads to enhancement of CREB activity.  
 
AMPK positively regulates IL-10 activation of mTORC1/S6K pathway 
Activity of the kinase complex mTORC1 is promoted by Akt phosphorylation of 
mTOR on Ser2448 (204, 230) and by Akt phosphorylation/inhibition of the mTORC1 
inhibitory protein tuberous sclerosis complex protein 2 (TSC2) (residue Thr1462 and 
Ser939) (231, 232).  On the other hand, AMPK restricts mTORC1 activity by 
phosphorylation/activation of TSC2 (residue Ser1345 and Thr1227) under conditions of 
energy stress in non-immune cells to limit energy consuming metabolic pathways (223).  
In contrast, in macrophages, transfection with a constitutively active form of CaMKIα, an 
AMPK upstream kinase, resulted in dramatically elevated AMPK activation accompanied 
by enhanced mTORC1-Ser2448 phosphorylation and treatment with AMPK inhibitor 
Compound C abolished this effect, indicating positive regulation of mTORC1 by AMPK 
(224).  Emerging evidence support a negative role of mTORC1 to regulate inflammatory 
responses in myeloid immune cells (221, 222).  Given the observed AMPK-dependent 
Akt activation in response to IL-10 stimulation (Fig. 18), the role of mTORC1 in this 
signaling pathway was evaluated.  We found that IL-10 stimulus induced phosphorylation 
of mTOR-Ser2448 in AMPKα1+/+ macrophages with a peak of ~1.5 fold increase at 30 
min post-stimulus.  However, in comparison with AMPKα1+/+ macrophages, both 
baseline and IL-10-induced levels of phospho-mTOR-Ser2448 were reduced in 
AMPKα1-/- cells (Fig. 20A).  In consistent, the CA-AMPKα1 macrophages, elevated 




















Figure 20. AMPK positively regulates IL-10 activation of mTORC1/S6K pathway.  (A),  
BMDM generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 
(20 ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for 
p-mTOR (Ser2448) and t-mTOR expression.  (B), CA-AMPKα1, DN-AMPKα1, and the 
control macrophage cell line were treated with rm-IL-10 (20ng/ml) for indicated time.  
Cell lysates were analyzed by Western blot for p-ACC (Ser79), t-ACC, p-mTOR 




Figure 20, continued.  (C and D), BMDM generated from AMPKα1+/+ and AMPKα1-/- 
mice were treated with rm-IL-10 (20 ng/ml) for the time points indicated.  Cell lysates 
were analyzed by Western blot for (C) p-p70 S6K (Ser371) and t-p70 S6K expression, 
and (D) p-TSC2 (Ser939), p-TSC2 (Ser1387), t-TSC2, and β-actin expression.  Protein 
phosphorylation and expression levels were analyzed by densitometry and are displayed 





















phosphorylation on Ser2448 (Fig. 20B).  This positive regulation of AMPK with 
mTORC1 activity was further demonstrated by the phosphorylation of p70 S6 Kinase 
(p70 S6K), a key downstream substrate of mTORC1, which, likewise, was efficiently 
activated by IL-10 in AMPKα1+/+, but not AMPKα1-/- macrophages (Fig. 20C).  
Meanwhile, there was no influence of IL-10 on the phosphorylation levels of either 
TSC2-Ser939 (Akt substrate) or Ser1387 (AMPK substrate) in either AMPKα1+/+ or 
AMPKα1-/- BMDM (Fig. 20D).  These data suggest a positive role of AMPK in IL-10-
induced mTORC1 activation via enhancement of PI3K/Akt activity, a regulatory effect 
that is TSC2-independent in macrophages.   
 
AMPK is required for IL-10 activation of JAK/STAT3/SOCS3 pathway 
The JAK/STAT3/SOCS3 signaling cascade is an important contributor to the 
antiinflammatory activity of IL-10 (184, 210, 211).  JAK kinase activity is responsible for 
IL-10 induced STAT3 tyrosine phosphorylation.  However, phosphorylation at both 
tyrosine and serine residues is necessary for STAT3 dimerization, translocation to the 
nucleus, and binding to the promoter regions of the socs3 gene to initiate SOCS3 protein 
expression.  SOCS3 is a rapidly produced and quickly degraded protein with a potent 
ability to suppress TLR-mediated inflammation (185, 219, 220).  In our evaluation of the 
role of AMPK in IL-10-induced JAK/STAT3/SOCS3 pathway, ~4.5 fold increase of 
JAK1 phosphorylation was observed in AMPKα1+/+ BMDM, an effect that was greatly 
reduced in AMPKα1-/- BMDM (Fig. 21A).  To further address the relationship between 
IL-10 induced AMPK and JAK kinase activity, we pretreated BMDM generated from 













Figure 21. AMPK positively regulates JAKs activity in response to IL-10.  (A), BMDM 
generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 
ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for p-
JAK1 (Tyr1022/1023) and t-JAK1 expression.  JAK1 phosphorylation and expression 
levels were analyzed by densitometry and are displayed as a bar histogram.  (B), BMDM 
generated from C57BL/6 mice were incubated with either media alone, or with JAK2 
inhibitor AG490 (25 μM), or JAK3 inhibitor CP690, 550 (25 nM) for 1 h, then exposed 
to rm-IL-10 (20 ng/ml) for the time points indicated.  Cell lysates were analyzed by 
Western blot for AMPK-Thr172 phosphorylation.  The results shown are representative 








AG490 and the JAK 3 inhibitor CP-690, 550), then stimulated the cells with IL-10.  Cell 
lysates were collected at the time points shown in Fig. 21B for Western blot analysis of 
phospho-AMPK levels.  The efficacy of the JAK kinase inhibitors was demonstrated by 
impaired JAK phosphorylation in response to IL-10 stimulation (data not shown).  As 
shown in Fig. 21B, AMPK activation by IL-10 stimulation was not affected by pre-
treatment with these inhibitors.   
 
IL-10-induced JAK1 activation is accompanied with elevated phosphorylation of 
both STAT3 Tyr705 (Fig. 22A, upper panel) and Ser727 (Fig. 22A, lower panel) in 
AMPKα1+/+ BMDM, whereas AMPKα1-deficiency completely abrogated this influence 
of IL-10.  The phosphorylation of Tyr705 occurred within 5 min whereas the 
phosphorylation of Ser727 occurred with slightly delayed onset, but both phosphorylation 
events peaked at 30 min - 1h (Fig. 22A).  This AMPK-dependent STAT3 activation by 
IL-10 is further confirmed by the utilization of the pharmaceutical inhibitor STO-609 to 
block AMPK activity.  STO-609 at concentrations between 1-10 μg/ml (2.6 - 26 μM) 
effectively blocks AMPK signaling cascades via inhibition of its upstream regulatory 
kinase CaMKKβ (233).  BMDM derived from AMPKα1+/+ mice were pre-incubated 
with STO-609 (5 μM) for 1h prior to stimulation with IL-10.  Cell lysates were harvested 
at the indicated time points and were analyzed by Western blot for AMPK and STAT3 
phosphorylation.  Pre-incubation with STO-609 blocked IL-10 induced AMPKα-Thr172 
phosphorylation (Fig. 22B, upper panel) and inhibited IL-10-induced STAT3 
phosphorylation of both Tyr705 (Fig. 22B, upper panel) and Ser727 (Fig. 22B, lower 





















Figure 22. IL-10-induced STAT3/SOCS3 activation requires AMPK activity.  BMDM 
generated from AMPKα1+/+ and AMPKα1-/- mice were treated with rm-IL-10 (20 
ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for (A), 
STAT3-Tyr705 (upper panel) and STAT3-Ser727 (lower panel) phosphorylation, and (D, 















Figure 22, continued. (B), BMDM generated from C57BL/6 mice were incubated with 
either media alone, or with CaMKKβ inhibitor STO-609 (5 µM) for 1 h, then exposed to 
rm-IL-10 (20 ng/ml) for the time points indicated.  Cell lysates were analyzed by Western 
blot for AMPK-Thr172, STAT3-Tyr705 (upper panel) and STAT3-Ser727 (lower panel) 
phosphorylation.  (C), CA-AMPKα1, DN-AMPKα1, and the control macrophage cell 
line were treated with rm-IL-10 (20ng/ml) for indicated time.  Cell lysates were analyzed 
by Western blot for STAT3-Tyr705 phosphorylation.  STAT3 activation levels were 
analyzed by densitometry and are displayed as a bar histogram.  (D, lower panel), CA-
AMPKα1 and the control macrophage cell line were treated with rm-IL-10 (20ng/ml) for 
indicated time.  Cell lysates were analyzed by Western blot for SOCS3 and β-actin 






CA-AMPKα1 macrophages also supported a positive role of AMPK in promoting IL-10 
activation of STAT3 (Fig. 22C).   In our analysis of SOCS3 mRNA in response to IL-10, 
an example of which is shown in Fig. 8, we observed SOCS3 mRNA accumulation in 
less than 30 min in AMPKα1+/+ cells (data not shown).  Consistent with this result, IL-
10 treatment induced the rapid appearance of SOCS3 protein in AMPKα1+/+ cells, which 
peaked at 30 min - 1h, yet we were unable to detect SOCS3 protein in IL-10-stimulated 
AMPKα1-/- BMDM (Fig. 22D upper panel).  Measurement of SOCS3 in CA-AMPKα1 
macrophages revealed a more stable baseline expression (Fig. 22D lower panel), 
providing the supportive evidence of AMPK positive regulation of SOCS3 stable 
expression. 
 
Data in Figures 21 and 22 suggested an essential role of AMPK in promoting IL-
10-induced activation of JAK/STAT3 pathway that leads to expression of SOCS3 protein.    
 
mTORC1 activity is required for optimal STAT3 activation  
The AMPK-dependency of both tyrosine and serine phosphorylation of STAT3 
suggested the possible convergence of AMPK-directed tyrosine kinase (JAK1) activities 
and serine kinase (mTORC1) activities in IL-10-directed STAT3 activation.  Data in 
Figures 21 and 22 provided evidence of AMPK-directed Jak1 kinase activity.  The 
mTORC1 inhibitor rapamycin was used to determine a possible role of mTORC1 in the 
IL-10-mediated serine phosphorylation of STAT3.  Pretreatment of BMDM with 
rapamycin suppressed IL-10-induced S6K phosphorylation (Fig. 23A, upper panel), 

















Figure 23. Inhibition of mTORC1 activity leads to impaired STAT3 phosphorylation.  
BMDM generated from C57BL/6 mice were incubated with either media alone, or with 
the mTORC1 inhibitor rapamycin (100 ng/ml) for 1 h and then exposed to rm-IL-10 (20 
ng/ml) for the time points indicated.  Cell lysates were analyzed by Western blot for (A) 
p70 S6K-Ser371 (upper panel) and AMPK-Thr172 (lower panel) phosphorylation and (B) 
STAT3-Ser727 (upper panel) and STAT3-Tyr705 (lower panel) phosphorylation.  




















Figure 23, continued. Protein phosphorylation levels were analyzed by densitometry and 













resulted in blockade of STAT3 Ser727 phosphorylation (Fig. 23B, upper panel), without 
effect on Tyr705 phosphorylation (Fig. 23B, lower panel).   
 
The results in Figures 20-23 indicate an upstream role of AMPK in the activation 
of both the tyrosine kinase (JAK1) and serine kinase (mTORC1) activities necessary for 
optimal activation of STAT3 via IL-10 stimulation in macrophages.    
 
AMPK contributes to IL-10 suppression of LPS-induced proinflammatory cytokine 
production 
The STAT3/SOCS3 pathway has been shown to play a major role in IL-10 
suppression of LPS-induced TLR inflammation.  For example, overexpression of a 
constitutively active form of STAT3 mimicked IL-10 suppression of LPS-induced TNFα 
and IL-6 production in primary human macrophages (234).  In contrast, deficiency of 
STAT3 expression in murine macrophages resulted in an inability of IL-10 to inhibit LPS-
induced TNFα production (214).  In addition, it has been reported that macrophages 
derived from mice with myeloid-specific STAT3-deletion produce significantly increased 
TNFα, IL-6, and IL-12 in response to LPS stimulation, and the ability of IL-10 to limit 
LPS-induced TNFα and IL-6 production is greatly reduced in these macrophages (235).  
SOCS3 was found to be responsible for IL-10 inhibition of LPS-induced TNFα and NO 
production in macrophages (220).  Our data indicating AMPK’s role in induction of 
STAT3 activation and SOCS3 expression suggested that AMPK activity should impact 
IL-10’s suppressive influence on TLR responses in macrophages.  As shown in Fig. 6, 





Figure 24. AMPK contributes to IL-10-mediated suppression of LPS-induced TNFα (A), 
IL-6  (B) and IL-12p40 production (C).  BMDM generated from AMPKα1+/+ and 
AMPKα1-/- mice were treated with rm-IL-10 (20 ng/ml) for 6h, then exposed to LPS (10 




Figure 24, continued.  Total cellular lysates were collected for real-time PCR analysis 
(left panels).  The ability of IL-10 to suppress LPS-mediated responses, based on the RT-
PCR data, is depicted as % suppression (middle panels).  Supernatants were collected for 
analysis by ELISA (right panels).  RT-PCR data shown are mean ± SD of triplicate 
determinations.  ELISA data shown are mean ± SEM of triplicate determinations.  
Statistical significance between groups was calculated with an unpaired Student’s t test, 
with a value of p < 0.050 considered statistically significant. (**, p < 0.001.  *, p < 0.050.  



















TNFα, IL-6, and IL-12p40 in both AMPKα1+/+ and AMPKα1-/- BMDM at the mRNA 
and protein (ELISA) levels.  As we have shown previously, AMPKα1-/- BMDM 
produced higher levels of TNFα and IL-6 (14, 15) and, in addition, higher levels of IL-
12p40 (Fig. 24).   Pre-treatment with IL-10 resulted in strong suppression (~80%) of 
LPS-induced TNFα, IL-6, and IL-12p40 mRNA transcription (Fig. 24).  However, in 
AMPKα1-/- BMDM, IL-10 suppression of LPS-induced expression of TNFα and IL-6 
was nearly absent, and suppression of IL-12p40 expression was substantially reduced as 
compared to that observed in AMPKα1+/+ BMDM (Fig. 24).    
 
Overall, our data suggest an essential role of AMPK in regulating IL-10 
suppressive signaling pathways that promotes immune suppressive functions of 
macrophages induced by IL-10 (Fig. 25).  AMPK is quickly activated by IL-10 
stimulation in macrophages.  IL-10 signaling promotes the rapid phosphorylation of 
JAK1 in an AMPK-dependent manner.  Activation of JAK1 subsequently leads to the 
phosphorylation and activation of STAT3 (Tyr 705), which is critical for SOCS3 
production.  In addition to its role in JAK/STAT signaling, AMPK also simultaneously 
promotes the activation of PI3K by enhancing the phosphorylation of its p55 
subunit.  Phospho-activation of Akt rapidly follows, leading to an increase in mTORC1 
activity as reflected by an increase in S6K phosphorylation (Ser371).  Activation of 
mTORC1 leads to an increase in phosphorylation of STAT3 (Ser727), which further 
enhances STAT3 transcriptional activity leading to SOCS3 production. Expression of 
SOCS3 in turn suppresses TLR-activated inflammatory cytokines 




downstream CREB activation that is responsible for IL-10 production that enhances 


























Figure 25. AMPK activation promotes the antiinflammatory properties of IL-10 
through bifurcated activation of the Akt/mTORC1 and JAK/STAT signaling 
pathways.  IL-10 signaling promotes the rapid phosphorylation of JAK1 in an AMPK-
dependent manner. Activation of JAK1 subsequently leads to the phosphorylation and 
activation of STAT3 (Tyr 705), which is critical for SOCS3 production.  In addition to its 
role in JAK/STAT signaling, AMPK also simultaneously promotes the activation of PI3K 
by enhancing the phosphorylation of the p55 subunit.  Phospho-activation of Akt rapidly 
follows, leading to an increase in mTORC1 activity, reflected by an increase in S6K 
phosphorylation (Ser371). Activation of mTORC1 leads to an increase in 
phosphorylation of STAT3 (Ser727), which further enhances STAT3 transcriptional 
activity leading to SOCS3 production. Expression of SOCS3 in turn suppresses TLR-






Macrophages display profound phenotypic and functional heterogeneity due to 
their ability to adapt to the tissue microenvironment (1).  This functional plasticity is 
crucial to their response to tissue damage, clearance of pathogens, contribution to 
adaptive immune responses, and wound resolution.  Macrophages can respond rapidly 
and reversibly to cytokine stimuli and in doing so can change functional phenotype (7).  
The ability of macrophages to be polarized to inflammatory and antiinflammatory states, 
e.g., via treatment with LPS + IFNγ or IL-4, respectively, has been studied extensively 
for over a decade, including attempts to elucidate the intracellular signaling pathways 
controlling the polarization process (236, 237).  We identified AMPK as a negative 
regulator of LPS-induced inflammatory responses in macrophages and dendritic cells via 
induction of a PI3K/Akt/GSK3β/CREB pathway and inhibition of NF-κB activity (14, 
15).   Likewise, Yang et al., reported that AMPK activity inhibited fatty acid-induced 
inflammation in macrophages in a SIRT1-dependent manner (109).   In the current report 
we follow-up on the finding that antiinflammatory cytokines such as IL-10, IL-4 and 
TGFβ are efficient activators of AMPK (14) and examined the role of AMPK in IL-10 
signal transduction and antiinflammatory function.      
IL-10 induces expression of a number of genes encoding proteins with 




of whether or not AMPKα1 contributes to IL-10-induced gene expression.  Our data 
provide direct evidence that IL-10 induces mRNA transcription of important 
atheroprotective genes in macrophages including apoE, LXRα, and ABCA1, as well as 
the immune suppressive SOCS family proteins in an AMPK-dependent manner (Fig. 8).  
The influence of AMPKα1 on apoE expression is supported by the matching data that 
macrophages transfected with constitutively active-AMPKα1 expressed ~ 60 fold higher 
apoE mRNA as compared to empty-vector transfected macrophages, while macrophages 
transfected with AMPKα1 siRNA did not express apoE in response to IL-10 (Fig. 9A and 
C).  Interestingly, as is the case for AMPK (14), ApoE has been recognized as a regulator 
of macrophage plasticity that promotes an antiinflammatory “M2-like” phenotype (182, 
183).   
SOCS3 is rapidly induced by IL-10 and potently inhibits inflammatory responses 
in many cell types including macrophages (185, 186).  Our data demonstrate a 
requirement for AMPKα1 expression for IL-10 induced SOCS3 expression at both the 
mRNA (Fig. 8) and protein (Fig. 22D upper panel) level.  This positive regulatory role of 
AMPKα1 in SOCS3 expression is also supported by the elevated SOCS3 protein 
expression in constitutively active-AMPKα1 transfected macrophages as compared to 
empty-vector transfected macrophages (Fig. 22D lower panel).   In our investigation of 
the mechanisms underlying AMPK’s role in IL-10-mediated SOCS3 expression we found 
that IL-10 induced rapid PI3K activation at 5-15 min (Fig. 14) and phosphorylation of 
both Akt Thr308 and Akt Ser473 (Fig. 18).  The Akt downstream target mTORC1 was 
likewise activated as indicated by both mTOR phosphorylation and phosphorylation of 




events were reduced in AMPKα1-/- BMDM as compared to BMDM derived from 
AMPKα1+/+ mice (Figs. 18 and 20).  Neither the PI3K inhibitor LY294002 nor the 
mTORC1 inhibitor rapamycin affected IL-10 induced AMPK activity (Fig. 15 and Fig. 
23), indicating an upstream regulatory role of AMPK IL-10 activation of the 
PI3K/Akt/mTOR pathway.   
Phosphorylation of Akt at Thr308 is mediated by PDK1, downstream of PI3K.  
Thus, the upstream role of AMPK can explain its impact on phosphorylation of Akt on 
this site.  The Rictor-mTOR complex (mTORC2) has been suggested to mediate 
phosphorylation of Akt Ser473 (238, 239).  However, the regulatory mechanism of 
mTORC2 activation is still poorly understood.  The demonstration that IL-10 induces 
phosphorylation of Akt at Ser473 in an AMPK-dependent manner suggests that AMPK 
influences mTORC2 activity in macrophages via an as yet undescribed mechanism.    
Akt is a central mediator of many signaling cascades involved in different 
biological processes.  PI3K/Akt/GSK3β pathway is one of those cascades that take 
responsibility to IL-10 suppression of LPS-induced proinflammatory gene expression via 
the inhibition of NF-κB activation (190, 206).  Our previous research demonstrated that 
CA-AMPKα1 macrophages display elevated phosphorylation/inactivation of GSK3β 
accompanied with increased CREB phosphorylation/activation in response to LPS 
stimulation (14).  We therefore investigated if IL-10 signaling also initiates the activation 
of this pathway.  Phosphorylation level of GSK3β stayed intact in both AMPKα1+/+ and 
AMPKα1-/- BMDM in response to IL-10 stimulation (Fig. 19A), whereas IL-10 
stimulation induced diminished CREB activation in DN-AMPKα1 compared to control 




mTORC1 (221) and CREB (240) are suggested to be responsible for IL-10 gene 
expression.  Although other mechanisms may provide feedback compensation effects on 
GSK3β activity based on the unresponsiveness of GSK3β phosphorylation by IL-10 
stimulation (Fig. 19A), the positive regulation between AMPK and CREB activation (Fig. 
19B) and between AMPK and mTORC1 (Fig. 20) both suggested that AMPK is 
important for IL-10 activation of PI3K/Akt downstream pathways that lead to 
antiinflammatory responses such as IL-10 production in macrophages.  
Studies on non-immune cells have shown that mTORC1 activity is negatively 
regulated via phosphorylation/activation of TSC2 on by AMPK (residue Ser1387 and 
Thr1227) under conditions of energy stress, and is positively regulated via 
phosphorylation/inactivation of TSC2 (Ser929) by Akt in response to insulin stimulation 
(223, 231).  Additionally, Akt positively regulates mTORC1 activity via direct 
phosphorylation of mTOR-Ser2448 residue (204).  In our study we observed decreased 
mTOR-Ser2448 in AMPKα1-/- BMDM but did not observe changes in phosphorylation 
of either TSC2 Ser1387 or TSC2 Ser939 levels in AMPKα1+/+ or AMPKα1-/- BMDM in 
response to IL-10 (Fig. 20D).  These data suggest that the AMPK’s influence on 
mTORC1 in macrophages in response to IL-10 stimulation is Akt-dependent, but 
independent of TSC2.   
Activation of the PI3K/Akt/mTORC1 pathway in macrophages is shown to elicit 
an antiinflammatory phenotype including induction of IL-10 expression (190, 191, 221, 
222).  Activated mTORC1 can also influence STAT3 activity via phosphorylation of 
STAT3 on Ser727.  We found diminished STAT3 phosphorylation on both Tyr705 and 




with an inhibitor of CaMKKβ, an upstream activator of AMPK (Figs. 22).  The data 
suggest that STAT3 in response to IL-10 is a two-step mechanism involving AMPK 
dependent regulation of both JAK kinase and mTORC1-mediated STAT3 
phosphorylation.  This conclusion is supported by our observation that both JAK1 and 
mTOR phosphorylation were impaired in AMPKα1-/- BMDM in response to IL-10 
stimulation (Figs. 21A and 20A), and that pretreatment with JAKs inhibitors (AG490 and 
CP-690, 550) or mTORC1 inhibitor (rapamycin) did not affect IL-10 induced AMPK and 
PI3K activation (Figs. 21B, 23A, and data not shown).  The impaired STAT3 activity in 
AMPKα1-/- BMDM is accompanied by diminished SOCS3 protein production (Fig. 
22D), a result that is consistent with the reduced SOCS3 mRNA level observed in 
AMPKα1-/- BMDM (Fig. 8).   
The lack of SOCS3 expression in response to IL-10 stimulation in AMPKα1-/- 
BMDM suggested that the suppressive function typically induced by IL-10 would likely 
by impaired.   Indeed, our data revealed a notable contribution of AMPKα1 towards the 
ability of IL-10 to suppress LPS-induced macrophage proinflammatory cytokine 
production (Fig. 24).  In addition to activation of the STAT3/SOCS3 pathway, a number 
of other mechanisms have been shown to mediate IL-10’s suppressive function.  For 
example, prolonged IL-10 pre-incubation is able to suppress LPS-induced TNFα 
production in the absence of SOCS3 expression in macrophages (220).  Proposed 
mechanisms for IL-10 suppression of LPS-induced IL-12p40 production include reduced 
RNA polymerase II recruitment to the p40 promoter (241) and promoter histone 
deacetylation (242).  A role for both STAT3/SOCS3 dependent and independent 




AMPKα1-deficiency on IL-10 suppression of LPS-induced IL-12p40 expression (Fig. 
24C).   
 
Thus far, our evaluation of myeloid-expressed AMPKα1 reveals its function as a 
counter-regulator of inflammatory signaling pathways induced, for example, via TLR and 
CD40 stimulation (14, 15) and as a mediator of the suppressive function of the 
antiinflammatory cytokine, IL-10.  Given the ability of numerous antiinflammatory 
mediators to rapidly activate AMPK in myeloid cells (14), it is likely that AMPK is a 
common upstream component of multiple signaling pathways, independent of metabolic 
stress.  Although IL-10 activation of AMPK may impact downstream metabolic 
pathways, the AMPK-dependent antiinflammatory function induced by IL-10 appears to 
be independent of this effect.   IL-10 is well-established as a critical mediator of immune 
homeostasis, in mice and humans, with the ability to dampen the destructive effects of 
inflammation in numerous pathologies (160).   Thus, the identification of AMPK as a 
mediator of IL-10 action supports continued exploration of therapies directed towards the 







CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Macrophages are extremely versatile immune cells with the remarkable ability to 
rapidly and reversibly respond to cytokine stimuli and adaptively change their functional 
phenotype (7).  This functional plasticity is critically correlated to atherosclerosis disease 
progression and recession (127, 128).  The physiological microenvironment within 
atherosclerosis lesions contains diverse factors with opposite roles in inflammation.  For 
example, IFNγ and IL-10, have the potential to promote macrophage functions that are 
either atherogenic or antiatherogenic, repectively.  Attempts to elucidate the intracellular 
signaling pathways controlling macrophage polarization process have been studied 
extensively for over a decade (236, 237).   
Herein, we present data that supports an essential role of AMPK in mediating IL-
10 triggered signaling events that lead to acquisition of antiinflammatory functions of 
macrophages as well as expression of atheroprotective genes such as apoE, LXRα, 
ABCA1, PPARγ, etc. (Figs. 8, 9 and 12) and inhibition of LPS-induced proinflammatory 
cytokine productions such as TNFα, IL-6, and IL-12p40 (Fig. 24).  Macrophage-specific 
expression of DN-AMPKα1 in transgenic mice resulted in spontaneous obesity 
associated with fatty liver, heart enlargement, and increased proinflammatory cytokine 




phenotype of DN-AMPKα1 mice was lost in their F2 offspring after an animal 
maintenance facility change, possibly due to the variation in the composition of 
residential bacteria (243), the critical role of macrophage expressed AMPK in the 
regulation of atherosclerosis was further supported by data showing decreased expression 
of the inflammatory cytokine IL-6 (Fig. 6A) but increased expression of the 
atheroprotective proteins ABCA1 (Fig. 7B) and apoE (Fig. 9A) in the CA-AMPKα1 
macrophages.  These data suggested an important role of macrophage-expressed AMPK 
in the regulation of whole body metabolic and inflammatory homeostasis.   Additionally, 
a co-dependent relationship was discovered between AMPK and the atheroprotective 
transcriptional factor PPARγ (Figs. 10 and 12).  In this co-dependent relationship, 
PPARγ-mediated IL-10 production was suggested to be responsible for PPARγ agonist-
induced AMPK activation at time points > 3h after treatment (Fig. 11).  These results 
provide plausible evidence for an important regulatory role of AMPK in macrophage 
antiatherogenic functions and contribute to the search for the therapeutic targets for 
atherosclerosis.   
 
Further investigation demonstrated a vital role of AMPK in mediating signaling 
pathways that are responsible for IL-10 immune regulatory functions.   These AMPKα1-
regulated pathways include IL-10 activation of PI3K/Akt/CREB, PI3K/Akt/mTORC1, 
and JAK/STAT/SOCS3 pathways.   
Our data showed rapid AMPK activation by IL-10 stimulation in macrophages 
(Fig. 13), which was found essential for IL-10 activation of PI3K (Fig.14), and then 




implied to be stimulated by IL-10 in pro-myeloid cells (191), our data showed for the first 
time that elevated phosphorylation/activation of PI3K by IL-10 in macrophage occurs 
through an AMPK-dependent mechanism.  The new insight provides important 
information for the understanding of IL-10 signaling pathways.   
Supportive data of AMPK regulation in IL-10 induced PI3K/Akt pathway include 
that constitutively active AMPK activity in macrophages resulted in decreased PTEN 
phosphorylation on the residues that are important to maintain PTEN stability, which 
may be responsible for the reduced PTEN levels (202) in these macrophages (Fig. 16A).  
Deficient expression of AMPKα1 in macrophages led to impaired overall expression and 
slightly reduced phosphorylation of PDK1 (Fig. 17), a kinase that phosphorylates Akt-
Thr308 and promotes Akt activation.  In agreement with these data, the result shown in 
Figure 18 clearly demonstrated a requirement for AMPKα1 in IL-10 activation of Akt on 
both threonine and serine residues, both of which contribute to optimal activation of Akt.  
Thus, an essential role of AMPK in the regulation of IL-10 activation of PI3K/Akt 
signaling pathway is demonstrated for the first time in macrophages. 
Further investigation of this pathway included examination of two downstream 
targets of Akt, CREB (Fig. 19) and mTORC1 (Fig. 20).  A mechanism for AMPK’s 
enhancement of CREB activity was demonstrated in CA-AMPKα1 macrophage cell line 
stimulated with LPS (14), however the underling mechanism between LPS and IL-10 
crosstalk is not fully understood.  Our data suggested a positive role of AMPK activity to 
enhance IL-10-induced activation of CREB (Fig.19), therefore providing a possible 
mechanism to understand the crosstalk between IL-10 and LPS.  It has been well 




mTORC1 activity via phosphorylation on TSC2-Ser1387 (223), however our data 
suggested a TSC2-independent but Akt-dependent mechanism by which AMPK enhances 
mTORC1 activity in response to IL-10 stimulation in macrophages (Fig. 20).  This 
conclusion was confirmed by the fact that inhibition of mTORC1 activity by the inhibitor 
rapamycin failed to suppress IL-10 induced AMPK activation (Fig. 23A), and is 
consistent with the observation by Guo, et al. that AMPK activity is positively associated 
with mTORC1 activity in macrophages (224).  This groundbreaking discovery suggests a 
need to reconsider carefully the use of AMPK activators such as metformin in the 
treatment of inflammation-associated diseases such as in atherosclerosis or cancer, as 
these drugs may influence inflammatory signaling pathways in immune cells totally 
separate from the effects they have on the metabolic pathways in non-immune cells 
including SMCs or tumor cells.  For example, although metformin may reduce tumor 
growth, it may also suppress anti-tumor immunity by boosting IL-10’s 
immunosuppressive functions. 
Another important discovery is that our data suggested a requirement for both 
JAK-mediated tyrosine phosphorylation and mTORC1-mediated serine phosphorylation 
of STAT3, both of which are regulated by AMPK.   Activation of the JAK/STAT3 
pathway by IL-10 is well established, however, a requirement for a second signal in 
addition to JAK tyrosine phosphorylation to mediate IL-10-induced STAT3 function was 
suggested (214) but never elucidated in the literature.  It has also been suggested that 
mTORC1-mediated serine-727 phosphorylation is important for STAT3 optimal 
activation (215-218), however the significance of this phosphorylation event in IL-10 




22) and mTORC1 (Fig.23), we are able to identify the critical regulatory role of AMPK 
in mediating optimal STAT3 activation via both tyrosine and serine phosphorylation in 
response to IL-10 stimulation in macrophages.  This conclusion provided an answer to 
the unresolved search for a secondary signal in mediating IL-10 activation of 
JAK1/STAT3 pathway, and contributes to the understanding of the IL-10 signaling 
puzzle. 
Finally, the IL-10-induced signaling cascades mediated by AMPK in macrophages 
led to the production of SOCS3 (Figs. 8 and 23D), which is recognized as a potent 
mediator of IL-10 suppressive functions.  Impaired SOCS3 production due to the lack of 
AMPKα1 expression contributes to the inability of AMPKα1-deficient macrophages to 
efficiently suppress LPS-induced proinflammatory cytokine production (Fig. 24), 
confirming the key role of AMPK in mediating IL-10 suppressive functions in 
macrophages.   
 
Thus far, the research in this dissertation provides a body of evidence to 
demonstrate an IL-10 initiated signaling network regulated at several critical points by 
AMPK (Fig. 25), which mediate macrophage antiinflammatory functions.  The findings 
have broad-reaching implications for our understanding the mechanism of IL-10 action in 
the maintenance of the immune homeostasis, as well as in inflammation-associated 
diseases where IL-10 plays a key role in limiting excessive inflammatory responses, such 
as in atherosclerosis (166), bowel disease (188), EAE (189), and cancer (244, 245).  The 
mechanisms discovered in this dissertation also contribute to our understanding of the 




example, treatment with the AMPK activator AICAR led to protective effects in EAE 
(102) and colitis (103).  Another AMPK activator, metformin, has been used to treat T2D 
and atherosclerosis (69, 70) and recently the use of metformin has been suggested to have 
beneficial effects in reducing tumor growth (246).  However the mechanisms of these 
drugs are not fully understood.   
 
Therefore, this study in the understanding of AMPK as a key regulator of IL-10 
suppressive pathways in macrophages has great values in answering the question of what 
is the underlying mechanism of both macrophage polarization and IL-10 
antiinflammatory functions that has been investigated over decades (210, 236, 237), and 
also has provided additional insights into the use of AMPK as a therapeutic target to treat 
inflammation-associated diseases such as atherosclerosis, autoimmune diseases and 
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